



---

# FINANCIAL STATEMENTS

---

FOR THE FISCAL PERIOD ENDING JUNE 30, 2026



*July 9, 2026*

**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

*No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam*

**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam.

**FINANCIAL STATEMENTS****STATEMENT OF FINANCIAL POSITION**

(As of June 30, 2026)

Unit: VND

| ITEMS                                                                  | Code       | Note       | Ending balance         | Beginning balance      |
|------------------------------------------------------------------------|------------|------------|------------------------|------------------------|
| <b>ASSETS</b>                                                          |            |            |                        |                        |
| <b>A - CURRENT ASSETS</b>                                              | <b>100</b> |            | <b>744.056.997.295</b> | <b>777.726.903.970</b> |
| <b>I. Cash and cash equivalents</b>                                    | <b>110</b> | <b>V.1</b> | <b>43.530.273.751</b>  | <b>171.479.406.892</b> |
| 1. Cash                                                                | 111        |            | 37.530.273.751         | 125.493.642.022        |
| 2. Cash equivalents                                                    | 112        |            | 6.000.000.000          | 45.985.764.870         |
| <b>II. Short-term investments</b>                                      | <b>120</b> |            | <b>6.097.651.256</b>   | <b>6.097.651.256</b>   |
| 1. Trading securities                                                  | 121        | V.2a       | 1.097.651.256          | 1.097.651.256          |
| 2. Provisions for devaluation of securities trading                    | 122        |            | 0                      | 0                      |
| 3. Held-to-maturity investments                                        | 123        | V.2b       | 5.000.000.000          | 5.000.000.000          |
| 4. Allowance for impairment of short-term held-to-maturity investments | 124        |            | 0                      | 0                      |
| 5. Other short-term investments                                        | 125        |            | 0                      | 0                      |
| 6. Allowance for impairment of other short-term investments            | 126        |            | 0                      | 0                      |
| <b>III. Short-term receivables</b>                                     | <b>130</b> |            | <b>301.207.622.388</b> | <b>234.807.300.506</b> |
| 1. Short-term trade receivables                                        | 131        | V.3        | 184.303.813.820        | 154.328.616.775        |
| 2. Short-term prepayments to suppliers                                 | 132        | V.4        | 11.758.823.428         | 5.973.546.025          |
| 3. Short-term inter-company receivable                                 | 133        |            | 0                      | 0                      |
| 4. Receivable according to the progress of construction contract       | 134        |            | 0                      | 0                      |
| 5. Short-term loans receivable                                         | 135        | V.5a       | 109.694.204.013        | 79.105.856.579         |
| 6. Allowance for short-term doubtful debts                             | 136        | V.6        | -4.549.218.873         | -4.600.718.873         |
| 7. Deficit assets for treatment                                        | 137        |            | 0                      | 0                      |
| <b>IV. Inventories</b>                                                 | <b>140</b> |            | <b>370.901.850.586</b> | <b>341.450.986.601</b> |
| 1. Inventories                                                         | 141        | V.7        | 370.901.850.586        | 341.450.986.601        |
| 2. Allowance for inventories                                           | 142        |            | 0                      | 0                      |
| <b>V. Short-term biological assets</b>                                 | <b>150</b> |            | <b>0</b>               | <b>0</b>               |
| 1. Short-term livestock held for single harvest                        | 151        |            | 0                      | 0                      |
| 2. Seasonal crops or short-term plants held for single harvest         | 152        |            | 0                      | 0                      |
| 3. Allowance for impairment of short-term biological assets            | 153        |            | 0                      | 0                      |
| <b>VI. Other current assets</b>                                        | <b>160</b> |            | <b>22.319.599.314</b>  | <b>23.891.558.715</b>  |
| 1. Short-term prepaid expenses                                         | 161        | V.8a       | 551.929.939            | 703.417.818            |
| 2. Deductible VAT                                                      | 162        |            | 21.460.558.704         | 23.020.588.406         |
| 3. Taxes and other accounts receivable from the State                  | 163        | V.15       | 307.110.671            | 167.552.491            |
| 4. Trading Government bonds                                            | 164        |            | 0                      | 0                      |
| 5. Other current assets                                                | 165        |            | 0                      | 0                      |
| <b>B- NON-CURRENT ASSETS</b>                                           | <b>200</b> |            | <b>704.210.882.573</b> | <b>585.933.358.989</b> |
| <b>I. Long-term receivables</b>                                        | <b>210</b> |            | <b>43.115.227.680</b>  | <b>23.772.155.478</b>  |
| 1. Long-term trade receivables                                         | 211        |            | 0                      | 0                      |
| 2. Long-term prepayment to suppliers                                   | 212        |            | 0                      | 0                      |
| 3. Long-term inter-company receivable                                  | 213        |            | 0                      | 0                      |
| 4. Long-term inter-company receivable                                  | 214        |            | 0                      | 0                      |
| 5. Other long-term receivable                                          | 215        | V.5b       | 43.115.227.680         | 23.772.155.478         |
| 6. Allowance for long-term doubtful debts                              | 216        |            | 0                      | 0                      |
| <b>II. Fixed assets</b>                                                | <b>220</b> |            | <b>413.345.509.390</b> | <b>401.716.726.273</b> |
| 1. Tangible fixed assets                                               | 221        | V.9        | 315.854.563.416        | 321.849.395.361        |
| - Historical cost                                                      | 222        |            | 508.188.468.539        | 502.428.649.474        |
| - Accumulated depreciation                                             | 223        |            | -192.333.905.123       | -180.579.254.113       |
| 2. Financial leased assets                                             | 224        | V.10       | 79.361.104.603         | 61.718.901.019         |
| - Historical cost                                                      | 225        |            | 91.339.688.919         | 68.420.125.038         |
| - Accumulated depreciation                                             | 226        |            | -11.978.584.316        | -6.701.224.019         |
| 3. Intangible fixed assets                                             | 227        | V.11       | 18.129.841.371         | 18.148.429.893         |



| ITEMS                                                                  | Code       | Note  | Ending balance           | Beginning balance        |
|------------------------------------------------------------------------|------------|-------|--------------------------|--------------------------|
| - Initial cost                                                         | 228        |       | 20.510.164.376           | 20.510.164.376           |
| - Accumulated amortization                                             | 229        |       | -2.380.323.005           | -2.361.734.483           |
| <b>III. Long-term biological assets</b>                                | <b>230</b> |       | <b>0</b>                 | <b>0</b>                 |
| 1. Livestock held for repeated production                              | 231        |       | 0                        | 0                        |
| a) Immature livestock held for repeated production                     | 232        |       | 0                        | 0                        |
| b) Mature livestock held for repeated production                       | 233        |       | 0                        | 0                        |
| Historical cost                                                        | 234        |       | 0                        | 0                        |
| Accumulated depreciation                                               | 235        |       | 0                        | 0                        |
| 2. Long-term livestock held for single harvest                         | 236        |       | 0                        | 0                        |
| 3. Long-term crops or plants held for single harvest                   | 237        |       | 0                        | 0                        |
| 4. Allowance for impairment of long-term biological assets             | 238        |       | 0                        | 0                        |
| <b>IV. Investment property</b>                                         | <b>240</b> |       | <b>0</b>                 | <b>0</b>                 |
| - Historical costs                                                     | 241        |       | 0                        | 0                        |
| - Accumulated depreciation                                             | 242        |       | 0                        | 0                        |
| <b>V. Long-term assets in process</b>                                  | <b>250</b> |       | <b>212.723.331.237</b>   | <b>125.438.110.860</b>   |
| 1. Long-term work-in-process                                           | 251        |       | 0                        | 0                        |
| 2. Construction-in-progress                                            | 252        | V.12  | 212.723.331.237          | 125.438.110.860          |
| <b>VI. Long-term investments</b>                                       | <b>260</b> |       | <b>17.130.750.000</b>    | <b>17.130.750.000</b>    |
| 1. Investments in subsidiaries                                         | 261        |       | 0                        | 0                        |
| 2. Investments in joint ventures and associates                        | 262        | V.2c  | 17.130.750.000           | 17.130.750.000           |
| 3. Investments in other entities                                       | 263        |       | 0                        | 0                        |
| 4. Allowance for impairment of long-term investments in other entities | 264        |       | 0                        | 0                        |
| 5. Held-to-maturity investments                                        | 265        | V.2a  | 0                        | 0                        |
| 6. Allowance for impairment of long-term held-to-maturity investments  | 266        |       | 0                        | 0                        |
| <b>VII. Other non-current assets</b>                                   | <b>270</b> |       | <b>17.896.064.266</b>    | <b>17.875.616.378</b>    |
| 1. Long-term prepaid expenses                                          | 271        | V.8b  | 17.896.064.266           | 17.875.616.378           |
| 2. Deferred income tax assets                                          | 272        |       | 0                        | 0                        |
| 3. Long-term components and spare parts and accessories                | 273        |       | 0                        | 0                        |
| 4. Other non-current assets                                            | 274        |       | 0                        | 0                        |
| <b>TOTAL ASSETS</b>                                                    | <b>280</b> |       | <b>1.448.267.879.868</b> | <b>1.363.660.262.959</b> |
| <b>EQUITY AND LIABILITIES</b>                                          |            |       |                          |                          |
| <b>C - LIABILITIES</b>                                                 | <b>300</b> |       | <b>842.690.858.236</b>   | <b>909.239.635.478</b>   |
| <b>I. Current liabilities</b>                                          | <b>310</b> |       | <b>653.762.469.380</b>   | <b>792.607.200.373</b>   |
| 1. Short-term trade payables                                           | 311        | V.13  | 156.474.598.756          | 93.879.304.480           |
| 2. Short-term advances from customers                                  | 312        | V.14  | 7.710.516.798            | 9.460.079.631            |
| 3. Dividends and profit payable                                        | 313        | V.18  | 267.381.200              | 0                        |
| 4. Taxes and other obligations payable to State Budget                 | 314        | V.15  | 5.226.060.125            | 13.578.767.542           |
| 5. Payables to employees                                               | 315        |       | 0                        | 0                        |
| 6. Short-term accrued expenses                                         | 316        | V.16  | 845.299.074              | 1.570.510.420            |
| 7. Short-term inter-company payables                                   | 317        |       | 0                        | 0                        |
| 8. Payable according to the progress of construction contracts         | 318        |       | 0                        | 0                        |
| 9. Short-term unearned revenue                                         | 319        | V.17  | 141.249.674              | 4.172.755.675            |
| 10. Other short-term payables                                          | 320        | V.18  | 8.417.849.276            | 142.747.679.592          |
| 11. Short-term borrowings and financial leases                         | 321        | V.19a | 473.277.553.716          | 515.594.422.349          |
| 12. Provisions for short-term payables                                 | 322        |       | 0                        | 0                        |
| 13. Bonus and welfare funds                                            | 323        | V.20  | 1.401.960.761            | 11.603.680.684           |
| 14. Price stabilization fund                                           | 324        |       | 0                        | 0                        |
| 15. Trading Government bonds                                           | 325        |       | 0                        | 0                        |
| <b>II. Long-term liabilities</b>                                       | <b>330</b> |       | <b>188.928.388.856</b>   | <b>116.632.435.105</b>   |
| 1. Long-term trade payables                                            | 331        |       | 0                        | 0                        |
| 2. Long-term prepayment from customers                                 | 332        |       | 0                        | 0                        |
| 3. Long-term taxes and other payables to the State                     | 333        |       | 0                        | 0                        |
| 4. Long-term accrued expenses                                          | 334        |       | 0                        | 0                        |
| 5. Inter-company payables for operating capital                        | 335        |       | 0                        | 0                        |
| 6. Long-term inter-company payables                                    | 336        |       | 0                        | 0                        |
| 7. Long-term unearned revenue                                          | 337        | V.17  | 4.593.058.193            | 0                        |
| 8. Other long-term payables                                            | 338        |       | 0                        | 0                        |
| 9. Long-term borrowing and financial leases                            | 339        | V.19b | 184.335.330.663          | 116.632.435.105          |

| ITEMS                                                             | Code       | Note | Ending balance           | Beginning balance        |
|-------------------------------------------------------------------|------------|------|--------------------------|--------------------------|
| 10. Convertible bonds                                             | 340        |      | 0                        | 0                        |
| 11. Preferred shares                                              | 341        |      | 0                        | 0                        |
| 12. Deferred income tax payable                                   | 342        |      | 0                        | 0                        |
| 13. Provisions for long-term payables                             | 343        |      | 0                        | 0                        |
| 14. Science and technology development funds                      | 344        |      | 0                        | 0                        |
| <b>D - OWNER'S EQUITY</b>                                         | <b>400</b> |      | <b>605.577.021.632</b>   | <b>454.420.627.481</b>   |
| 1. Capital                                                        | 411        | V.21 | 358.104.210.000          | 266.152.680.000          |
| - Ordinary shares carrying voting right                           | 411a       |      | 358.104.210.000          | 266.152.680.000          |
| - Preferred shares                                                | 411b       |      |                          |                          |
| 2. Share premiums                                                 | 412        | V.21 | 106.529.056.700          | 34.984.290.700           |
| 3. Bond conversion option                                         | 413        |      | 0                        | 0                        |
| 4. Other sources of capital                                       | 414        |      | 0                        | 0                        |
| 5. Treasury stocks                                                | 415        |      | 0                        | 0                        |
| 6. Differences on asset revaluation                               | 416        |      | 0                        | 0                        |
| 7. Foreign exchange differences                                   | 417        |      | 0                        | 0                        |
| 8. Investment and development fund                                | 418        | V.21 | 114.368.190.306          | 101.242.219.168          |
| 9. Other funds                                                    | 419        |      | 0                        | 0                        |
| 10. Retained earnings                                             | 420        | V.21 | 26.575.564.626           | 52.041.437.613           |
| - Retained earnings accumulated to the end of the previous period | 420a       |      | 0                        | 0                        |
| - Retained earnings of the current period                         | 420b       |      | 26.575.564.626           | 52.041.437.613           |
| <b>TOTAL LIABILITIES AND OWNER'S EQUITY</b>                       | <b>440</b> |      | <b>1.448.267.879.868</b> | <b>1.363.660.262.959</b> |

Approved on July 9, 2026



Do Thi Kim Len  
Preparer

Pham Do Phuong Thao  
Acting Chief Accountant

Nguyen Van Kha  
Legal Representative





**INCOME STATEMENT**  
For the Second Quarter of 2026

Unit: VND

| ITEMS                                                          | Code | Note   | Current year          | Previous year         | Year-to-date<br>(Current year) | Year-to-date<br>(Previous year) |
|----------------------------------------------------------------|------|--------|-----------------------|-----------------------|--------------------------------|---------------------------------|
| 1. Sales                                                       | 01   | VI.1   | 245.085.693.981       | 207.380.145.149       | 454.079.483.173                | 409.783.064.337                 |
| 2. Sales deductions                                            | 02   | VI.2   | 1.397.727.420         | 754.223.581           | 2.465.773.672                  | 1.857.624.031                   |
| 3. Net sales                                                   | 10   |        | 243.687.966.561       | 206.625.921.568       | 451.613.709.501                | 407.925.440.306                 |
| 4. Cost of sales                                               | 11   | VI.4   | 173.966.516.903       | 145.873.917.791       | 321.791.799.134                | 291.752.118.991                 |
| 5. Gross profit                                                | 20   |        | 69.721.449.658        | 60.752.003.777        | 129.821.910.367                | 116.173.321.315                 |
| 6. Gain/(loss) on disposal of investment property              | 21   |        | 0                     | 0                     | 0                              | 0                               |
| 7. Financial income                                            | 22   | VI.5   | 276.555.206           | 208.799.206           | 610.176.077                    | 274.353.608                     |
| 8. Financial expenses                                          | 23   | VI.6   | 13.197.879.103        | 11.464.245.249        | 23.568.722.010                 | 20.856.576.319                  |
| In which: Loan interest expenses                               | 24   |        | 12.478.784.428        | 10.193.607.418        | 22.393.087.563                 | 18.880.133.246                  |
| 9. Selling expenses                                            | 25   | VI.7   | 28.102.853.869        | 24.446.196.067        | 51.200.867.087                 | 46.914.133.258                  |
| 10. General and administration expenses                        | 26   | VI.8   | 13.247.225.738        | 11.321.032.155        | 23.457.817.381                 | 21.478.189.285                  |
| 11. Share of profit or loss in joint ventures and associates   | 27   |        | 0                     | 0                     | 0                              | 0                               |
| 12. Net operating profit                                       | 30   |        | 15.450.046.154        | 13.729.329.512        | 32.204.679.966                 | 27.198.776.061                  |
| 13. Other income                                               | 31   | VI.9   | 204.324.982           | 263.373.191           | 220.821.182                    | 3.158.686.633                   |
| 14. Other expenses                                             | 32   |        | 0                     | 115.000               | 0                              | 115.000                         |
| 15. Other profit                                               | 40   |        | 204.324.982           | 263.258.191           | 220.821.182                    | 3.158.571.633                   |
| 16. Total accounting profit before tax                         | 50   |        | 15.654.371.136        | 13.992.587.703        | 32.425.501.148                 | 30.357.347.694                  |
| 17. Current income tax                                         | 51   | V.15   | 2.579.566.170         | 2.633.923.971         | 5.849.936.522                  | 5.906.875.969                   |
| 18. Deferred income tax                                        | 52   |        | 0                     | 0                     | 0                              | 0                               |
| 19. Profit after tax                                           | 60   |        | <u>13.074.804.966</u> | <u>11.358.663.732</u> | <u>26.575.564.626</u>          | <u>24.450.471.725</u>           |
| 20. Profit after tax attributable to owners of the Parent      |      |        | 0                     | 0                     | 0                              | 0                               |
| 21. Profit after tax attributable to non-controlling interests |      |        | 0                     | 0                     | 0                              | 0                               |
| 22. Earning per share                                          | 70   | VI.10a | <u>445</u>            | <u>515</u>            | <u>418</u>                     | <u>866</u>                      |
| 23. Diluted earning per share                                  | 71   | VI.10a | <u>445</u>            | <u>515</u>            | <u>418</u>                     | <u>866</u>                      |

Approved on July 9, 2026

Do Thi Kim Len  
Preparer

Pham Do Phuong Thao  
Acting Chief Accountant



Nguyen Van Kha  
Legal Representative

**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam.

**FINANCIAL STATEMENTS**
**CASH FLOW STATEMENT**

(Full format)

(Indirect method)

For the Second Quarter of 2026

|                                                                                                    |      |                             | Unit: VND                      |                                 |
|----------------------------------------------------------------------------------------------------|------|-----------------------------|--------------------------------|---------------------------------|
| ITEMS                                                                                              | Code | Note                        | Year-to-date<br>(Current year) | Year-to-date<br>(Previous year) |
| <b>I. Cash flows from operating activities</b>                                                     |      |                             |                                |                                 |
| 1. Profit before tax                                                                               | 01   |                             | 32.425.501.148                 | 30.357.347.694                  |
| 2. Adjustments                                                                                     |      |                             |                                |                                 |
| - Depreciation of fixed assets                                                                     | 02   | V.9, V.10,<br>V.11          | 18.407.554.185                 | 18.433.774.920                  |
| - Provisions                                                                                       | 03   | V.6                         | (51.500.000)                   | 277.861.521                     |
| - Gain/ (loss) from exchange difference due to revaluation of monetary items in foreign currencies | 04   | VI.5                        | 106.041.144                    | 330.989.924                     |
| - Gain/(loss) from investing and financing activities                                              | 05   | VI.5, VI.10                 | (484.139.689)                  | (2.873.454.392)                 |
| - Interest expenses                                                                                | 06   | VI.6                        | 22.393.087.563                 | 18.880.133.246                  |
| - Other adjustments                                                                                | 07   |                             | -                              | -                               |
| 6. Operating profit before changes of working capital                                              | 08   |                             | 72.796.544.351                 | 65.406.652.913                  |
| - Increase/(decrease) of receivables                                                               | 09   |                             | (78.915.682.886)               | 3.545.851.030                   |
| - Increase/(decrease) of inventories                                                               | 10   |                             | (29.450.863.985)               | (54.024.013.974)                |
| - Increase/(decrease) of payables                                                                  | 11   |                             | (58.230.481.007)               | 8.576.455.329                   |
| - Increase/ (decrease) of prepaid expenses                                                         | 12   |                             | 131.039.991                    | (1.935.457.635)                 |
| - Increase/(decrease) of securities trading                                                        | 13   |                             | -                              | -                               |
| - Interests paid                                                                                   | 14   |                             | (22.255.066.319)               | (18.914.083.482)                |
| - Corporate income tax paid                                                                        | 15   | V.15                        | (14.202.643.939)               | (11.722.011.234)                |
| - Other cash inflows                                                                               | 16   |                             | -                              | -                               |
| - Other cash outflows                                                                              | 17   | V.20                        | (12.392.326.398)               | (7.043.893.569)                 |
| Net cash flows from operating activities                                                           | 20   |                             | (142.519.480.192)              | (16.110.500.622)                |
| <b>II. Cash flows from investing activities</b>                                                    |      |                             |                                |                                 |
| 1. Purchases and construction of fixed assets and other long-term assets                           | 21   | V.4,V.9,V.10,<br>V.12, V.13 | (137.743.420.248)              | (76.395.909.620)                |
| 2. Proceeds from disposals of fixed assets and other long-term assets                              | 22   |                             | 22.969.663.881                 | 9.010.746.737                   |
| 3. Cash outflow for lending, buying debt instruments of other entities                             | 23   |                             | -                              | -                               |
| 4. Cash recovered from lending, selling debt instruments of other entities                         | 24   |                             | -                              | -                               |
| 5. Investments into other entities                                                                 | 25   |                             | -                              | -                               |
| 6. Withdrawals of investments in other entities                                                    | 26   |                             | -                              | -                               |
| 7. Interest earned, dividends and profits received                                                 | 27   | V.5a, VI.5                  | 323.853.938                    | -                               |
| Net cash flows from investing activities                                                           | 30   |                             | (114.449.902.429)              | (67.385.162.883)                |
| <b>III. Cash flows from financing activities</b>                                                   |      |                             |                                |                                 |
| 1. Proceeds from issuing stocks and capital contributions from owners                              | 31   |                             | 126.771.436.000                | 20.829.546.000                  |
| 2. Repayment for capital contributions and re-purchases of stocks already issued                   | 32   |                             | -                              | -                               |
| 3. Receivables from borrowings                                                                     | 33   | V.19a,b                     | 375.269.998.246                | 388.120.415.179                 |
| 4. Repayment for loan principal                                                                    | 34   | V.19a                       | (343.959.232.839)              | (285.313.193.660)               |



| ITEMS                                             | Code      | Note       | Year-to-date<br>(Current year) | Year-to-date<br>(Previous year) |
|---------------------------------------------------|-----------|------------|--------------------------------|---------------------------------|
| 5. Payments for financial leased assets           | 35        | V.19a,b    | (29.051.894.086)               | (10.607.151.926)                |
| 6. Dividends and profit paid to the owners        | 36        | V.21d      | -                              | (11.343.723.000)                |
| <i>Net cash flows from financing activities</i>   | <i>40</i> |            | <u>129.030.307.321</u>         | <u>101.685.892.593</u>          |
| <b>Net cash flows during the period</b>           | <b>50</b> |            | <b>(127.939.075.300)</b>       | <b>18.190.229.088</b>           |
| <b>Beginning cash and cash equivalents</b>        | <b>60</b> | <b>V.1</b> | <b>171.479.406.892</b>         | <b>13.948.008.363</b>           |
| Effects of fluctuations in foreign exchange rates | 61        |            | (10.057.841)                   | 9.551.829                       |
| <b>Ending cash and cash equivalents</b>           | <b>70</b> | <b>V.1</b> | <u><b>43.530.273.751</b></u>   | <u><b>32.147.789.280</b></u>    |

Approved on July 9, 2026



*[Handwritten signature]*

Do Thi Kim Len  
Preparer

*[Handwritten signature]*

Pham Do Phuong Thao  
Acting Chief Accountant

Nguyen Van Kha  
Legal Representative

**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

---

**NOTES TO THE FINANCIAL STATEMENTS**

For the Second Quarter of 2026

**I. GENERAL INFORMATION****1. Ownership form**

Agimexpharm Pharmaceutical Joint Stock Company (hereinafter referred to as "the Company") is a joint stock company.

**2. Business field**

The Company's business fields are industrial production and trading.

**3. Principal business activities**

Principal business activities of the Company are to manufacture medicines, pharmaceutical chemicals and pharmaceutical materials; trade optical, medical, dental and hospital equipment; trade medicines, pharmaceutical products; trade nutritious food; produce and trade cosmetics; trade materials and ancillary materials, pharmaceutical chemicals for pharmaceutical production; trade vaccines and medical biological products; manufacture bottled water (the Company must comply with the Law on food safety and hygiene during operation course); manufacture dietary supplements; manufacture, trade and process essential oil from herbs; manufacture and trade food, nutritious food and dietary supplements.

**4. Normal operating cycle**

Normal operating cycle of the Company is within 12 months.

**5. Structure of the Company*****Joint venture***

The Company only invests in USA-AGP Phamra, LLC headquartered at No. 14314 Brookhurst Street, Garden Grove City, California, 92843. Principal business activities of this joint venture are to package and trade bottled capsules and tablets of dietary supplements, pharmaceutical products, reishi, cordyceps. As of the balance sheet date, the Company's capital contribution rate at this joint venture is 43,24%. This capital contribution rate has not been complete as specified. However, according to the Business Cooperation Contract No. 01/HDHTKD dated March 18, 2019, the voting percentage is 50% equivalent to the ownership percentage.

**6. Statement of information comparability on the Financial Statements**

The figures in the current year can be comparable with corresponding figures in the previous year.

**7. Headcount**

As of the balance sheet date, the Company's headcount is 500 (headcount at the beginning of the year: 489).

**II. FISCAL YEAR AND ACCOUNTING CURRENCY UNIT****1. Fiscal year**

The fiscal year of the Company is from 01 January to 31 December annually.

**2. Accounting currency unit**

The accounting currency unit is Vietnamese Dong (VND) because the Company's transactions are primarily made in VND.



## **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### **FINANCIAL STATEMENTS**

---

### **III. APPLICABLE ACCOUNTING STANDARDS AND SYSTEM**

#### **1. Applicable Accounting System**

The Company applies Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting Regime issued under Circular No. 99/2025/TT-BTC dated October 27, 2025, and related guiding circulars issued by the Ministry of Finance for the preparation and presentation of its financial statements.

#### **2. Statement of the compliance with the Accounting Standards and System**

The Board of Management confirms that the Company has complied with Vietnamese Accounting Standards, the Vietnamese Enterprise Accounting Regime issued under Circular No. 99/2025/TT-BTC dated October 27, 2025, and relevant guiding circulars issued by the Ministry of Finance in the preparation and presentation of its financial statements.

### **IV. APPLICABLE ACCOUNTING POLICIES**

#### **1. Accounting convention**

All the Financial Statements are prepared on the accrual basis (except for the information related to cash flows).

#### **2. Foreign currency transactions**

Transactions denominated in foreign currencies are converted at the exchange rates ruling as of the transaction dates. The balances of monetary items denominated in foreign currencies at the end of the accounting period are converted at the exchange rates prevailing on that date.

Foreign exchange differences arising from foreign currency transactions during the year shall be included into financial income or financial expenses. Foreign exchange differences arising from the revaluation of foreign currency-denominated monetary items at the end of the accounting period, after netting out increases and decreases, shall be included into financial income or financial expenses.

The exchange rate used to convert foreign currency transactions is the actual exchange rate ruling as at the time of these transactions. The actual exchange rates applied to foreign currency transactions are as follows:

- For the foreign currency trading contract (including spot contract, forward contract, future contract, option contract, currency swap): the exchange rate stipulated in the contracts of trading foreign currency between the Company and the Bank.
- For receivables: the buying rate ruling as at the time of transaction of the commercial bank where the Company designates the customers to make payments.
- For payables: the selling rate ruling as at the time of transaction of the commercial bank where the Company supposes to make payments.
- For acquisition of assets or immediate payments in foreign currency (not included into payable accounts): the buying rate of the commercial bank where the Company makes payments.

The exchange rates used to re-evaluate the ending balances of monetary items in foreign currencies are determined according to the following principles:

- For foreign currency deposits: the buying rate of the bank where the Company opens its foreign currency account.
- For monetary items in foreign currencies classified as other assets: the buying rate of VietinBank – An Giang Branch where the Company frequently conducts transactions.



## AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### FINANCIAL STATEMENTS

---

- For monetary items in foreign currencies classified as liabilities: the selling rate of VietinBank – An Giang Branch where the Company frequently conducts transactions.

#### 3. Cash and cash equivalents

Cash include cash on hand and cash in bank.

#### 4. Financial investments

##### *Trading securities*

Investments classified as trading securities are those held by the Company for the trading purpose with the aim of making profit.

Trading securities are recognized at costs. The cost of trading securities is determined based on the fair value of payments at the time the transaction plus other costs directly attributable to the acquisition of the trading securities.

The time of recognizing trading securities is when the Company acquires the ownership, as follows:

- For listed securities: recognized at the time of order-matching (T+0).
- For unlisted securities: recognized at the time of acquiring official ownership as stipulated by law.

Interest, dividends, and profit incurred prior to the acquisition of trading securities are deduced into costs of these securities. Interest, dividends and profit incurred after the acquisition of such securities are recorded in the Company's financial income.

Provisions for devaluation of trading securities are made for each particular type of securities in the market of which the fair value is lower than original costs. The fair value of trading securities is determined as follows:

- For securities listed on the stock market: the closing price at the most recent trading date by the balance sheet date.
- For shares registered for trading on UPCOM and State-owned enterprises equitized by offering shares for sales to public: the average reference price in the 30 most preceding trading days prior to the balance sheet date, disclosed by Stock Exchange.
- For shares listed on the stock market or shares registered for trading on Upcom without transactions within 30 days prior to the date of provision, the shares which are delisted, canceled or suspended from trading: provision is made based on the losses of the investee at the rate equal to the difference between the actual capital invested by the owners and owner's equity as of the balance sheet date multiplying by the ownership rate over the total actual charter capital invested.

Increases/(decreases) in the provisions for devaluation of trading securities as at the balance sheet date are recorded into financial expenses.

Gain or loss from transfer of trading securities is recognized into financial income or financial expenses. The costs are determined in accordance with the mobile weighted average method.

##### *Held-to-maturity investments*

An investment is classified as a held-to-maturity investment when the Company has the intention and ability to hold it to maturity. The Company's held-to-maturity investments include term deposits for the purpose of collecting periodical interest and other held-to-maturity investments.



## **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### **FINANCIAL STATEMENTS**

---

Held-to-maturity investments are initially recognized at cost including the acquisition cost and other transaction costs. After initial recognition, these investments are recorded at recoverable value. Interest income from these held-to-maturity investments after acquisition date is recognized in the Income Statement on an accrual. Interest incurred prior to the Company's acquisition of held-to-maturity investments is deducted into the costs as at the acquisition time.

When there are reliable evidence proving that a part or the whole investment cannot be recovered and the loss are reliably determined, the loss is recognized as financial expenses during the year while the investment value is derecognized.

#### ***Investments in joint venture***

##### ***Joint venture***

A joint venture is an entity which is established by a contractual arrangement whereby the Company and the involved parties undertake an economic activity that is subject to joint control. Joint control is the contractually agreed sharing of control over an economic activity, and exists only when the strategic financial and operating decisions relating to the activity require the unanimous consent of the venturers.

##### ***Initially recognition***

Investments in joint venture are initially recognized at costs, including the cost of purchase or capital contributions plus other directly attributable transaction cost. In case of investment in non-monetary assets, the costs of the investment are recognized at the fair value of non-monetary assets at the arising time.

Dividends and profits incurred prior to the purchase of investments are deducted into the investment costs. Dividends and profit incurred after the purchase of investments are recorded into the Company's financial statements.

##### ***Provisions for impairment of investments in joint venture***

Provisions for impairment of investments in joint venture are made when the joint venture suffers from losses at the rate equal to the difference between the actual capital invested by investors in joint venture and the actual owner's equity multiplying (x) by the Company's rate of capital contribution over the total actual capital invested by investors in the subsidiary. If the subsidiary is consolidated into Consolidated Financial Statements, the basis for impairment provisions is the Consolidated Financial Statements.

Increases/(decreases) in the provisions for impairment of investments in joint venture as of the balance sheet date are recorded into financial expenses.

## **5. Receivables**

Receivables are recognized at the carrying amounts less allowances for doubtful debts.

The classification of receivables as trade receivables and other receivables is made according the following principles:

- Trade receivables reflect receivables concerning the commercial nature arising from purchase and sale transactions between the Company and customers who are independent to the Company.
- Other receivables reflect receivables not concerning the commercial nature and irrelevant to purchase and sale transactions.

Allowance is made for each doubtful debt on the basis of estimated loss.



## AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### FINANCIAL STATEMENTS

---

Increases/(decreases) in the obligatory allowance for doubtful debts as of the balance sheet date are recorded into general and administration expenses.

#### 6. Inventories

Inventories are recognized at the lower of cost or net realizable value.

Cost of inventories is determined as follows:

- For materials and merchandise: Costs comprise costs of purchases and other directly relevant costs incurred in bringing the inventories to their present location and conditions.
- Work-in-process: Costs comprise costs of main materials only.
- For finished goods: Costs comprise costs of materials, direct labor and directly relevant general manufacturing expenses allocated on the basis of normal operations.

Stock-out costs are determined in accordance with the weighted average method and recorded in line with the perpetual method.

Net realizable value is the estimated selling price of inventories in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.

Allowance for devaluation of inventories is recognized for each type of inventories when their costs are higher than their net realizable values. Increases/(decreases) in the obligatory allowance for inventories as of the balance sheet date are recorded into costs of sales.

#### 7. Prepaid expenses

Prepaid expenses comprise actual expenses arising and relevant to financial performance in several accounting periods. Prepaid expenses of the Company mainly include:

##### *Tools*

Expenses of tools being put into use are allocated into cost in accordance with the straight-line method for the maximum period of 03 years.

##### *Expenses of fixed asset repairs*

Expenses of fixed asset repairs arising once with high value are allocated into cost in accordance with the straight-line method in 03 years.

#### 8. Tangible fixed assets

Tangible fixed assets are presented at historical costs less accumulated depreciation. Historical costs of tangible fixed assets comprise all costs incurred by the Company to acquire the assets up to the time when it is brought to its working condition for its intended use. Subsequent costs are added to historical costs of fixed assets only if it is probable that future economic benefits associated with the asset will flow to the Company. Subsequent costs that do not meet the above conditions will be recognized as operation costs during the year.

Upon disposal or liquidation of a tangible asset, its historical cost and accumulated depreciation are derecognized, then any gain or loss resulting from such disposal is included in the income or the expenses during the year.

Tangible fixed assets are depreciated in accordance with the straight-line method over their estimated useful lives. The depreciation years applied are as follows:

| <u>Fixed assets</u>      | <u>Years</u> |
|--------------------------|--------------|
| Buildings and structures | 05 – 25      |
| Machinery and equipment  | 02 – 15      |



## AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### FINANCIAL STATEMENTS

---

| <u>Fixed assets</u> | <u>Years</u> |
|---------------------|--------------|
| Vehicles            | 05 – 10      |
| Office equipment    | 03 – 10      |

#### 9. Financial leased assets

A lease is classified as a finance lease if it transfers substantially all the risks and rewards incident to ownership belonging to the lessee. Financial leased assets are determined by their historical costs less accumulated depreciation. Historical cost is the lower cost of the fair value of the leased asset at commencement of the lease term and the present value of the minimum lease payments. Discount rate used to calculate the present value of the minimum lease payments is the interest rate implicit in the lease or else mentioned in the lease. If the interest rate implicit in the lease cannot be determined, the incremental borrowing rate at commencement of the lease term will be applied.

Financial leased assets are depreciated in accordance with the straight-line method over their estimated useful lives. If there is no reasonable certainty that the Company will obtain ownership at the end of the lease, the fixed asset shall be depreciated over the shorter of the lease term and the estimated useful life of the asset. The depreciation years of the financial leased assets are as follows:

| <u>Fixed assets</u>     | <u>Years</u> |
|-------------------------|--------------|
| Machinery and equipment | 03 – 15      |

#### 10. Intangible fixed assets

Intangible fixed assets are presented at initial costs less accumulated amortization.

Initial costs of intangible fixed assets include all costs incurred by the Company to acquire the assets up to the time when it is brought to its working condition for its intended use. Subsequent costs relevant to intangible fixed assets are recognized as operation costs during the period in which they are incurred, unless such costs are directly attributable to a specific intangible asset and increase the future economic benefits expected to be derived from that asset.

Upon disposal or liquidation of an intangible asset, its initial costs and accumulated amortization are derecognized, then any gain or loss resulting from such disposal is included in the income or the expenses during the year.

The Company's intangible fixed assets include:

##### *Land use right*

Land use right includes all the actual expenses paid by the Company directly related to the land being used such as expenses to obtain the land use right, expenses for house removal, land clearance and ground leveling, registration fees, etc. The land use right is amortized in accordance with the straight-line method over the term specified on the land use right certificate (49 years). If the land use right is permanent, it is not amortized.

##### *Computer software*

Expenses attributable to computer software, which is not a part associated with the relevant hardware, will be capitalized. Costs of computer software include all the expenses paid by the Company until the date the software is put into use. Computer software is amortized in accordance with the straight-line method in 05 years.

#### 11. Construction-in-progress

Construction-in-progress reflects the expenses (including relevant loan interest expenses following the accounting policies of the Company) directly attributable to assets under construction,



## **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### **FINANCIAL STATEMENTS**

---

machinery and equipment under installation for purposes of production, leasing and management as well as the repair of fixed assets in progress. These assets are recorded at historical costs and not depreciated.

#### **12. Payables and accrued expenses**

Payables and accrued expenses are recorded for the amounts payable in the future associated with the goods and services received. Accrued expenses are recorded based on reasonable estimates for the amounts payable.

The classification of payables as trade payables, accrued expenses and other payables is made on the basis of following principles:

- Trade payables reflect payables of commercial nature arising from the purchase of goods, services, or assets, of which the seller is an independent entity with the Company, including payables for entrusted imports.
- Accrued expenses reflect expenses for goods, services received from suppliers or supplied to customers but have not been paid, invoiced or lack of accounting records and supporting documents; pay on leave payable to employees; and accrual of operation expenses.
- Other payables reflect payables of non-commercial nature and irrelevant to purchase, sales of goods or provisions of services.

The payables and accrued expenses are classified as short-term and long-term items in the Balance Sheet on the basis of their remaining term as of the balance sheet date.

#### **13. Owner's capital**

The owner's capital is recorded according to the actual amounts contributed by the shareholders.

##### ***Share premiums***

Share premiums are recorded in accordance with the difference between the issuance price and face value upon the IPO, additional issue or the difference between the re-issuance price and carrying value of treasury shares and the equity component of convertible bonds upon maturity date. Expenses directly related to the additional issue of shares and the re-issuance of treasury shares are recorded as a decrease in share premiums.

#### **14. Profit distribution**

Profit after tax is distributed to the shareholders after appropriation for funds under the Charter of the Company as well as legal regulations and after getting approval from the General Meeting of Shareholders.

The distribution of profits to the shareholders is made with consideration toward non-cash items in the retained earnings that may affect cash flows and payment of dividends such as profit due to revaluation of assets contributed as investment capital, profit due to revaluation of monetary items, financial instruments and other non-cash items.

Dividend is recorded as payables upon approval of the General Meeting of Shareholders and notification on dividend payment of the Board of Directors.

#### **15. Recognition of sales and income**

##### ***Revenue from sales of merchandises, finished goods***

Revenue from sales of merchandises, finished goods shall be recognized when all of the following conditions are satisfied:

- The Company transfers most of risks and benefits incident to the ownership of products or goods to customers.



## **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam  
**FINANCIAL STATEMENTS**

---

- The Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the products, goods sold.
- The amount of sales can be measured reliably. When the contracts stipulate that buyers have the right to return products, goods purchased under specific conditions, sales are recorded only when those specific conditions are no longer exist and buyers retains no right to return products, goods (except for the case that such returns are in exchange for other goods or services).
- The Company received or shall probably receive the economic benefits associated with sale transactions.
- The cost incurred or to be incurred in respect of the sale transaction can be measured reliably.

### ***Interest***

Interest is recorded, based on the term and the actual interest rate applied in each particular period.

### ***Dividends and profit shared***

Dividends and profit shared are recognized when the Company has the right to receive dividends or profit from the capital contribution. Particularly, the dividends paid in form of shares are not recorded as an increase in value, but the increasing quantity is followed up.

## **16. Revenue deductions**

Revenue deductions include trade discounts, sales allowances, sales returns incurred in the same period of providing products, merchandises, in which revenues are derecognized.

In case of products, merchandises provided in the previous years but trade discounts, sales allowances, sales returns incurred in the current year, revenues are derecognized as follows:

- If sales allowances, trade discounts, sales returns incur prior to the release of the Financial Statements, revenues are derecognized on the Financial Statements of the current year.
- If sales allowances, trade discounts, sales returns incur after the release of the Financial Statements, revenues are derecognized on the Financial Statements of the following year.

## **17. Borrowing costs**

Borrowing costs are interests and other costs that the Company directly incurs in connection with the borrowing.

Borrowing costs are recorded as an expense when it is incurred. In case the borrowing costs are directly attributable to the construction or the production of an asset in progress, which takes a substantial period of time (over 12 months) to get ready for intended use or sales of the asset, these costs will be included in the cost of that asset. To the extent that the borrowings are especially for the purpose of construction of fixed assets and investment properties, the borrowing cost is eligible for capitalization even if construction period is under 12 months. Incomes arisen from provisional investments as loans are recognized as a decrease in the costs of relevant assets.

In the event that general borrowings are partly used for the acquisition, construction or production of an asset in progress, the costs eligible for capitalization will be determined by applying the capitalization rate to average accumulated expenditure on construction or production of that asset. The capitalization rate is computed at the weighted average interest rate of the borrowings not yet paid during the year, except for particular borrowings serving the purpose of obtaining a specific asset.



## **AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

### **FINANCIAL STATEMENTS**

---

#### **18. Expenses**

Expenses are those that result in outflows of the Company's economic benefits and are recorded at the time of transactions or when incurrence of the transaction is reliable regardless of whether payment for expenses is made or not.

Expenses and their corresponding revenues are simultaneously recognized in accordance with matching principle. In the event that matching principle conflicts with prudence principle, expenses are recognized based on the nature and regulations of accounting standards in order to guarantee that transactions can be fairly and truly reflected.

#### **19. Corporate income tax**

Corporate income tax includes current income tax and deferred income tax.

##### ***Current income tax***

Current income tax is the tax amount computed based on the assessable income. The assessable income is different from accounting profit due to the adjustments of temporary differences between tax and accounting figures, non-deductible expenses as well as those of non-taxable income and losses brought forward.

##### ***Deferred income tax***

Deferred income tax is the amount of corporate income tax payable or refundable due to temporary differences between book values of assets and liabilities serving the preparation of the Financial Statements and the values for tax purposes. Deferred income tax liabilities are recognized for all the temporary taxable differences. Deferred income tax assets are recorded only when there is an assurance on the availability of assessable income in the future against which the temporarily deductible differences can be used.

Carrying values of deferred corporate income tax assets are considered as of the balance sheet date and will be reduced to the rate that ensures enough assessable income against which the benefits from part of or all of the deferred income tax can be used. Deferred corporate income tax assets, which have not been recorded before, are considered as of the balance sheet date and are recorded when there is certainly enough assessable income to use these unrecognized deferred corporate income tax assets.

Deferred income tax assets and deferred income tax liabilities are determined at the estimated rate to be applied in the year when the assets are recovered or the liabilities are settled based on the effective tax rates as of the balance sheet date. Deferred income tax is recognized in the Income Statement. In the case that deferred income tax is related to the items of the owner's equity, corporate income tax will be included in the owner's equity.

The Company shall offset deferred tax assets and deferred tax liabilities if:

- The Company has the legal right to offset current income tax assets against current income tax liabilities; and
- Deferred income tax assets and deferred income tax liabilities are relevant to corporate income tax which is under the management of one tax authority either:
  - Of the same subject to corporate income tax; or
  - The Company has intention to pay current income tax liabilities and current income tax assets on a net basis or recover tax assets and settle tax liability simultaneously in each future period to the extent that the majority of deferred income tax liabilities or deferred income tax assets are paid or recovered.



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS****20. Related parties**

A party is considered a related party of the Company in case that party is able to control the Company or to cause material effects on the financial decisions as well as the operations of the Company. A party is also considered a related party of the Company in case that party is under the same control or is subject to the same material effects.

Considering the relationship of related parties, the nature of relationship is focused more than its legal form.

**21. Segment reporting**

A business segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services and that is subject to risks and returns that are different from those of other business segments.

A geographical segment is a distinguishable component of the Company that is engaged in manufacturing or providing products or services within a particular economic environment and that is subject to risks and returns that are different from those of components operating in other economic environments.

Segment information is prepared and presented in compliance with the accounting policy in the preparation and presentation of the Financial Statements of the Company.

**V. ADDITIONAL INFORMATION ON THE ITEMS PRESENTED IN THE BALANCE SHEET****1. Cash**

|                                                                                                                   | <u>Ending balance</u>        | <u>Beginning balance</u>      |
|-------------------------------------------------------------------------------------------------------------------|------------------------------|-------------------------------|
| Cash on hand                                                                                                      | 7.815.584.089                | 7.860.159.984                 |
| Cash in bank <sup>(i)</sup>                                                                                       | 29.714.689.662               | 117.633.482.038               |
| Cash equivalents - <i>Bank deposits of which the principal maturity is from or under 3 months</i> <sup>(ii)</sup> | 6.000.000.000                | 45.985.764.870                |
| <b>Total</b>                                                                                                      | <b><u>43.530.273.751</u></b> | <b><u>171.479.406.892</u></b> |

<sup>(i)</sup> This deposit is guaranteed for the deposit to open L/C for machinery import at Vietinbank – An Giang Branch.

**2. Financial investments**

The financial investments of the Company include trading securities, held-to-maturity investments and investments in other entities. The Company's financial investments are as follows:

**2a. Trading securities**

|                                                      | <u>Ending balance</u>  |                    |                   | <u>Beginning balance</u> |                    |                   |
|------------------------------------------------------|------------------------|--------------------|-------------------|--------------------------|--------------------|-------------------|
|                                                      | <u>Original amount</u> | <u>Fair values</u> | <u>Provisions</u> | <u>Original amount</u>   | <u>Fair values</u> | <u>Provisions</u> |
| <b>Shares</b>                                        |                        |                    |                   |                          |                    |                   |
| Imexpharm Corporation                                | 1.052.350.306          | 6.515.203.200      | -                 | 1.052.350.306            | 8.302.140.000      | -                 |
| Mekophar Chemical Pharmaceutical Joint-Stock Company | 45.300.950             | 137.721.000        | -                 | 45.300.950               | 119.199.900        | -                 |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|       | Ending balance  |               |            | Beginning balance |               |            |
|-------|-----------------|---------------|------------|-------------------|---------------|------------|
|       | Original amount | Fair values   | Provisions | Original amount   | Fair values   | Provisions |
| Total | 1.097.651.256   | 6.652.924.200 | -          | 1.097.651.256     | 8.421.339.900 | -          |

**2b. Held-to-maturity investments**

|                                                                                              | Ending balance  |                | Beginning balance |                |
|----------------------------------------------------------------------------------------------|-----------------|----------------|-------------------|----------------|
|                                                                                              | Original amount | Carrying value | Original amount   | Carrying value |
| <i>Short-term</i>                                                                            |                 |                |                   |                |
| Term deposit with a maturity of 12 months, bearing interest at 4.2% per annum <sup>(i)</sup> | 5.000.000.000   | 5.000.000.000  | 5.000.000.000     | 5.000.000.000  |
| Total                                                                                        | 5.000.000.000   | 5.000.000.000  | 5.000.000.000     | 5.000.000.000  |

<sup>(i)</sup> This deposit has been mortgaged to secure the loans from VietinBank - An Giang Branch (see Note No. V.19a).

**2c. Investments in other entities**

|                                     | Ending balance  |            | Beginning balance |            |
|-------------------------------------|-----------------|------------|-------------------|------------|
|                                     | Original amount | Provisions | Original amount   | Provisions |
| <i>Investments in joint venture</i> |                 |            |                   |            |
| USA-AGP Pharma, LLC <sup>(i)</sup>  | 17.130.750.000  | -          | 17.130.750.000    | -          |
| Total                               | 17.130.750.000  | -          | 17.130.750.000    | -          |

<sup>(i)</sup> According to the Investment Certificate No. 201900695, registered for the first time on July 19, 2019 and amended for the first time on April 09, 2022, granted by the Ministry of Planning and Investment, the Company invests an amount of VND 19.663.050.000 (USD 850.000) into USA-AGP Pharma, LLC, equivalent to 50% of charter capital. As of the balance sheet date, the Company invested VND 17.130.750.000 (USD 735.000), equivalent to 43,24% of charter capital. The charter capital to be invested in USA-AGP Pharma, LLC is VND 2.532.300.000 (equivalent to USD 115.000). The operations of USA-AGP Pharma, LLC have not progressed as planned; therefore, Agimexpharm Pharmaceutical Joint Stock Company has decided to extend the timeline for remitting the remaining capital contribution as approved under the overseas investment registration certificate.

*Fair value*

Fair value of investments with listed price is measured at the listed price as of the balance sheet date. The Company has not measured the fair value of the investments without listed price because there is no available specific instruction on measurement of the fair value.

*Operation of the joint venture*

USA-AGP Pharma, LLC operates a manufacturing facility producing and trading capsule and tablet products packaged in bottles, including dietary supplements, herbal products, Ganoderma lucidum (lingzhi), and Cordyceps militaris. USA-AGP Pharma, LLC was granted a goods trading license on 15 February 2023 and officially commenced commercial operations in 2024.

*Transactions with the joint venture*

During the year, the Company incurred sales transactions to USA-AGP Pharma, LLC, a joint venture company, with the sales amount of VND 0 (the previous period: VND 716.327.070).



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS****3. Short-term trade receivables**

|                                         | <u>Ending balance</u>  | <u>Beginning balance</u> |
|-----------------------------------------|------------------------|--------------------------|
| <i>Receivables from related party</i>   | <i>3.367.107.470</i>   | <i>904.459.010</i>       |
| Imexpharm Corporation                   | 2.462.648.460          | -                        |
| USA-AGP Pharma, LLC                     | 904.459.010            | 904.459.010              |
| <i>Receivables from other customers</i> | <i>180.936.706.350</i> | <i>153.424.157.765</i>   |
| Pharmacy Pharmacy Joint Stock Company   | 15.046.355.889         | 12.909.406.111           |
| Other customers                         | 165.890.350.461        | 140.514.751.654          |
| <b>Total</b>                            | <b>184.303.813.820</b> | <b>154.328.616.775</b>   |

Some trade receivables, of which the ending balance of carrying value is VND 107.000.000.000, have been mortgaged to secure the loans from Banks (see Note No. V.19a).

**4. Short-term prepayments to suppliers**

|                                                | <u>Ending balance</u> | <u>Beginning balance</u> |
|------------------------------------------------|-----------------------|--------------------------|
| Kim Nam Tinh Machinery Manufacturing Co., Ltd. | 218.400.000           | 388.800.000              |
| Nguyen Phuc Mechanical Joint Stock Company     | -                     | 1.102.811.883            |
| National Institute of Drug Quality Control     | 900.000.000           | 1.507.920.000            |
| Other suppliers                                | 10.640.423.428        | 2.974.014.142            |
| <b>Total</b>                                   | <b>11.758.823.428</b> | <b>5.973.546.025</b>     |

|                                                                                  | <u>Ending balance</u> | <u>Beginning balance</u> |
|----------------------------------------------------------------------------------|-----------------------|--------------------------|
| <i>In which:</i>                                                                 |                       |                          |
| Short-term prepayments to suppliers for acquisition of fixed assets/construction | 7.349.985.000         | 2.101.594.011            |

**5. Other receivables****5a. Other short-term receivables**

|                                      | <u>Ending balance</u>  |                  | <u>Beginning balance</u> |                  |
|--------------------------------------|------------------------|------------------|--------------------------|------------------|
|                                      | <u>Value</u>           | <u>Allowance</u> | <u>Value</u>             | <u>Allowance</u> |
| Advances                             | 72.669.887.748         | -                | 36.804.570.162           | -                |
| Term deposit interest to be received | 200.958.904            | -                | 90.673.153               | -                |
| Short-term mortgages, deposits       | 24.986.294.263         | -                | 25.203.978.542           | -                |
| Other short-term receivables         | 11.837.063.098         | -                | 17.006.634.722           | -                |
| <b>Total</b>                         | <b>109.694.204.013</b> | <b>-</b>         | <b>79.105.856.579</b>    | <b>-</b>         |

**5b. Other long-term receivables**

These represent long-term deposits and security deposits.

**6. Doubtful debts**

|                                                                                 | <u>Ending balance</u>  |                           | <u>Beginning balance</u> |                           |
|---------------------------------------------------------------------------------|------------------------|---------------------------|--------------------------|---------------------------|
|                                                                                 | <u>Original amount</u> | <u>Recoverable amount</u> | <u>Original amount</u>   | <u>Recoverable amount</u> |
| Receivables from other organizations and individuals - <i>Trade receivables</i> | 4.549.218.873          | -                         | 4.600.718.873            | -                         |
| <b>Total</b>                                                                    | <b>4.549.218.873</b>   | <b>-</b>                  | <b>4.600.718.873</b>     | <b>-</b>                  |

Movements in the provision for short-term doubtful receivables are as follows:



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                   | <b>Ending<br/>balance</b> | <b>Beginning<br/>balance</b> |
|-------------------|---------------------------|------------------------------|
| Beginning balance | 4.600.718.873             | 4.375.357.352                |
| Provision         | (51.500.000)              | 225.361.521                  |
| <b>Total</b>      | <b>4.549.218.873</b>      | <b>4.600.718.873</b>         |

**7. Inventories**

|                        | <b>Ending balance</b>  |                  | <b>Beginning balance</b> |                  |
|------------------------|------------------------|------------------|--------------------------|------------------|
|                        | <b>Original costs</b>  | <b>Allowance</b> | <b>Original costs</b>    | <b>Allowance</b> |
| Materials and supplies | 205.584.675.337        | -                | 175.704.568.367          | -                |
| Work-in-process        | 23.582.929.579         | -                | 19.440.823.444           | -                |
| Finished goods         | 140.101.705.554        | -                | 144.671.276.715          | -                |
| Merchandise            | 1.583.144.100          | -                | 1.509.185.272            | -                |
| Goods on consignment   | 49.396.016             | -                | 125.132.803              | -                |
| <b>Total</b>           | <b>370.901.850.586</b> | <b>-</b>         | <b>341.450.986.601</b>   | <b>-</b>         |

Some inventories, of which the ending balance of carrying value is VND 255.000.000.000, have been mortgaged to secure the loans from Banks (see Note No. V.19a).

**8. Prepaid expenses****8a. Short-term prepaid expenses**

|                                   | <b>Ending balance</b> | <b>Beginning balance</b> |
|-----------------------------------|-----------------------|--------------------------|
| Expenses of tools                 | 76.031.745            | -                        |
| Asset insurance premiums          | 270.785.523           | 627.212.436              |
| Other short-term prepaid expenses | 205.112.671           | 76.205.382               |
| <b>Total</b>                      | <b>551.929.939</b>    | <b>703.417.818</b>       |

**8b. Long-term prepaid expenses**

|                                  | <b>Ending balance</b> | <b>Beginning balance</b> |
|----------------------------------|-----------------------|--------------------------|
| Expenses of tools                | 6.538.041.111         | 6.920.235.741            |
| Expenses of fixed asset repairs  | 4.057.469.422         | 5.247.988.497            |
| Other long-term prepaid expenses | 7.300.553.733         | 5.707.392.140            |
| <b>Total</b>                     | <b>17.896.064.266</b> | <b>17.875.616.378</b>    |

**9. Tangible fixed assets**

Increases/(decreases) of tangible fixed assets are presented in the attached Appendix 01.

Some tangible fixed assets, of which the carrying amount is VND 267.411.912.452, have been mortgaged to secure the loans from Banks (see Notes No. V.19a and V.19b).

**10. Financial leased assets**

|                                     | <b>Machinery and<br/>equipment</b> |
|-------------------------------------|------------------------------------|
| <b>Historical costs</b>             |                                    |
| Beginning balance                   | 68.420.125.038                     |
| Increase during the period          | 22.919.563.881                     |
| Purchase of financial leased assets | -                                  |
| <b>Ending balance</b>               | <b>91.339.688.919</b>              |
| <b>Depreciation</b>                 |                                    |
| Beginning balance                   | 6.701.224.019                      |
| Depreciation during the period      | 5.277.360.297                      |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                                     |                                |
|-------------------------------------|--------------------------------|
|                                     | <b>Machinery and equipment</b> |
| Purchase of financial leased assets | -                              |
| <b>Ending balance</b>               | <b>11.978.584.316</b>          |
| <b>Carrying amount</b>              |                                |
| <b>Beginning balance</b>            | <b>61.718.901.019</b>          |
| <b>Ending balance</b>               | <b>79.361.104.603</b>          |

**11. Intangible fixed assets**

|                                         | <b>Land use right (*)</b> | <b>Computer software</b> | <b>Total</b>          |
|-----------------------------------------|---------------------------|--------------------------|-----------------------|
| <b>Initial costs</b>                    |                           |                          |                       |
| <b>Beginning balance</b>                | <b>18.706.085.532</b>     | <b>1.804.078.844</b>     | <b>20.510.164.376</b> |
| Increase during the period              | -                         | -                        | -                     |
| Decrease during the period              | -                         | -                        | -                     |
| <b>Ending balance</b>                   | <b>18.706.085.532</b>     | <b>1.804.078.844</b>     | <b>20.510.164.376</b> |
| <i>In which:</i>                        |                           |                          |                       |
| Assets fully amortized but still in use | -                         | 1.804.078.844            | 1.804.078.844         |
| Assets waiting for liquidation          | -                         | -                        | -                     |
| <b>Amortization</b>                     |                           |                          |                       |
| <b>Beginning balance</b>                | <b>557.655.639</b>        | <b>1.804.078.844</b>     | <b>2.361.734.483</b>  |
| Amortization during the period          | 18.588.522                | -                        | 18.588.522            |
| <b>Ending balance</b>                   | <b>576.244.161</b>        | <b>1.804.078.844</b>     | <b>2.380.323.005</b>  |
| <b>Carrying amount</b>                  |                           |                          |                       |
| <b>Beginning balance</b>                | <b>18.148.429.893</b>     | <b>-</b>                 | <b>18.148.429.893</b> |
| <b>Ending balance</b>                   | <b>18.129.841.371</b>     | <b>-</b>                 | <b>18.129.841.371</b> |
| <i>In which:</i>                        |                           |                          |                       |
| Assets temporarily not in use           | -                         | -                        | -                     |
| Assets waiting for liquidation          | -                         | -                        | -                     |

(\*) In which, the land use right of which the net book values are VND 18.129.841.371 has been mortgaged to secure the loans from Banks (see Note No. V.19a).

**12. Construction-in-progress**

|                                                                | <b>Beginning balance</b> | <b>Increase during the period</b> | <b>Inclusion into fixed assets during the period</b> | <b>Transfer to long-term prepaid expenses</b> | <b>Ending balance</b>  |
|----------------------------------------------------------------|--------------------------|-----------------------------------|------------------------------------------------------|-----------------------------------------------|------------------------|
| <b>Acquisition of fixed assets</b>                             | <b>9.800.000.000</b>     | <b>-</b>                          | <b>-</b>                                             | <b>-</b>                                      | <b>9.800.000.000</b>   |
| <b>Construction-in-progress</b>                                | <b>115.638.110.860</b>   | <b>110.508.957.447</b>            | <b>(23.192.059.270)</b>                              | <b>(31.677.800)</b>                           | <b>202.923.331.237</b> |
| - Expansion project of the medicinal plant factory             | 17.737.827.916           | 14.013.241.852                    | -                                                    | -                                             | 31.751.069.768         |
| - Liquid Medicine Factory construction project                 | 75.967.225.964           | 4.398.901.110                     | -                                                    | -                                             | 80.366.127.074         |
| - Air filtration systems of Liquid Medicine Factory – Binh Hoa | 11.749.032.492           | 2.709.704.200                     | (14.458.736.692)                                     | -                                             | -                      |
| - Liquid dosage manufacturing line                             | -                        | 79.427.424.679                    | -                                                    | -                                             | 79.427.424.679         |
| - Other constructions                                          | 10.184.024.488           | 9.959.685.606                     | (8.733.322.578)                                      | (31.677.800)                                  | 11.378.709.716         |
| <b>Total</b>                                                   | <b>125.438.110.860</b>   | <b>110.508.957.447</b>            | <b>(23.192.059.270)</b>                              | <b>(31.677.800)</b>                           | <b>212.723.331.237</b> |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS****13. Short-term trade payables**

|                                                           | <u>Ending balance</u>  | <u>Beginning balance</u> |
|-----------------------------------------------------------|------------------------|--------------------------|
| <i>Payables to related party</i>                          | <i>3.852.697.837</i>   | <i>3.031.598.285</i>     |
| Imexpharm Corporation                                     | 3.852.697.837          | 3.031.598.285            |
| <i>Payables to other suppliers</i>                        | <i>153.820.359.385</i> | <i>90.847.706.195</i>    |
| Branch of Glandcore Company Limited                       | 26.416.604.692         | 15.843.717.996           |
| Khang Gia Design - Construction - Trading Company Limited | -                      | 10.367.407.336           |
| Other suppliers                                           | 126.205.296.227        | 64.636.580.863           |
| <b>Total</b>                                              | <b>156.474.598.756</b> | <b>93.879.304.480</b>    |

|                                                                        | <u>Ending balance</u> | <u>Beginning balance</u> |
|------------------------------------------------------------------------|-----------------------|--------------------------|
| <i>In which:</i>                                                       |                       |                          |
| Short-term trade payables for acquisition of fixed assets/construction | 660.404.652           | 15.783.370.430           |

**14. Short-term advances from customers**

|                                               | <u>Ending balance</u> | <u>Beginning balance</u> |
|-----------------------------------------------|-----------------------|--------------------------|
| Thien Dien Pharmaceutical Joint Stock Company | 2.585.587.935         | 2.999.999.997            |
| Global Pharmaceutical Joint Stock Company     | -                     | 1.908.674.679            |
| Ms Le Bich Ngoc                               | 719.550.021           | 717.987.229              |
| Duke University                               | 1.144.302.300         | 1.144.302.300            |
| Other customers                               | 3.261.076.542         | 2.689.115.426            |
| <b>Total</b>                                  | <b>7.710.516.798</b>  | <b>9.460.079.631</b>     |

**15. Taxes and other obligations to the State Budget**

|                        | <u>Beginning balance</u> |                    | <u>Increase during the period</u> |                         | <u>Ending balance</u> |                    |
|------------------------|--------------------------|--------------------|-----------------------------------|-------------------------|-----------------------|--------------------|
|                        | <u>Payables</u>          | <u>Receivables</u> | <u>Amount payable</u>             | <u>Amount paid</u>      | <u>Payables</u>       | <u>Receivables</u> |
| - VAT on local sales   | -                        | -                  | -                                 | -                       | -                     | -                  |
| - Export-import duties | -                        | -                  | 38.005.920                        | (59.648.648)            | -                     | 21.642.728         |
| - Corporate income tax | 13.578.767.542           | -                  | 5.849.936.522                     | (14.202.643.939)        | 2.925.916.507         | -                  |
| - Personal income tax  | -                        | 167.552.491        | 3.342.070.015                     | (3.459.985.467)         | -                     | 285.467.943        |
| - Property income tax  | -                        | -                  | 141.649.258                       | (141.649.258)           | -                     | -                  |
| <b>Total</b>           | <b>13.578.767.542</b>    | <b>167.552.491</b> | <b>9.371.661.715</b>              | <b>(17.863.927.312)</b> | <b>5.226.060.125</b>  | <b>307.110.671</b> |

**Value added tax (VAT)**

The Company has to pay VAT in accordance with the deduction method. The tax rates applied are as follows:

|                                                   |     |
|---------------------------------------------------|-----|
| - Medicines, pharmaceutical products of all kinds | 5%  |
| - Cosmetics and dietary supplements of all kinds  | 10% |

From 1 January 2025 to 30 June 2025, the Company was entitled to apply the 8% value-added tax ("VAT") rate to goods and services that were otherwise subject to the 10% VAT rate, in accordance with Government Decree No. 180/2024/ND-CP dated 31 December 2024.



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam  
**FINANCIAL STATEMENTS**

Pursuant to Article 2 of Government Decree No. 174/2025/ND-CP, the reduction of the VAT rate from 10% to 8% for the goods and services specified in Clause 1, Article 1 of Government Decree No. 174/2025/ND-CP is applicable from 1 July 2025 to 31 December 2026.

**Export-import duties**

The Company declares and pays these duties in accordance with notifications issued by the Customs authorities.

**Corporate income tax**

The Company has to pay corporate income tax at the rate of 20% on taxable income.

In 2020, the Company put Binh Hoa Pharmaceutical Factory into operation, which located in areas with special socio-economic difficulties. Pursuant to the current Law on Corporate Income Tax, the project is entitled to tax incentives at the tax rate of 17% in 10 years for income from business activities in this area; and is exempted from tax in 2 years and reduced 50% of the tax payable in the following 4 years. The year 2026 is the seventh year in which the Company is entitled to the preferential tax rate of 17% per annum.

The estimated corporate income tax payable during the year is as follows:

|                                                                              | <u>Current period</u> | <u>Previous period</u> |
|------------------------------------------------------------------------------|-----------------------|------------------------|
| Total accounting profit before tax                                           | 32.425.501.148        | 30.357.347.694         |
| Increases/(decreases) of accounting profit to determine taxable income:      | -                     | -                      |
| - Other increases                                                            | 174.000.000           | 504.694.855            |
| - Decreases                                                                  | (11.552.869)          | (13.775.089)           |
| Taxable income                                                               | 32.587.948.279        | 30.848.267.460         |
| Income exempted from tax                                                     | -                     | (2.374.500)            |
| Assessable income                                                            | 32.587.948.279        | 30.845.892.960         |
| Corporate income tax rate                                                    | 20%                   | 20%                    |
| <b>Corporate income tax payable at common tax rate</b>                       | <b>6.517.589.656</b>  | <b>6.169.178.592</b>   |
| <b>Differences due to the application of rate other than common tax rate</b> | <b>(100.147.970)</b>  | <b>(68.426.771)</b>    |
| <b>Corporate income tax reduced</b>                                          | <b>(567.505.164)</b>  | <b>(193.875.852)</b>   |
| <b>Corporate income tax to be paid</b>                                       | <b>5.849.936.522</b>  | <b>5.906.875.969</b>   |

Determination of corporate income tax liability of the Company is based on currently applicable regulations on tax. Nonetheless, these tax regulations may change from time to time and tax regulations applicable to variety of transactions can be interpreted differently. Hence, the tax amounts presented in the Financial Statements can be changed upon the inspection of tax authorities.

**Land rental, property tax**

Land rental is paid according to the notices of the tax department.

**Other taxes, fees, legal fees and other duties**

The Company has declared and paid these taxes in line with the prevailing regulations.

**16. Short-term accrued expenses**

|                                  | <u>Ending balance</u> | <u>Beginning balance</u> |
|----------------------------------|-----------------------|--------------------------|
| Loan interest expenses           | 845.299.074           | 707.277.830              |
| Commissions and sales promotions | -                     | 863.232.590              |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                                                                        | <u>Ending balance</u> | <u>Beginning balance</u> |
|------------------------------------------------------------------------|-----------------------|--------------------------|
| <b>Total</b>                                                           | <b>845.299.074</b>    | <b>1.570.510.420</b>     |
| <b>17. Short-term unearned revenues</b>                                |                       |                          |
| This item reflects the proceeds from sales of financial leased assets. |                       |                          |
| <b>18. Other short-term payables</b>                                   |                       |                          |
|                                                                        | <u>Ending balance</u> | <u>Beginning balance</u> |
| Trade Union's expenditure                                              | 348.023.486           | 318.295.624              |
| Dividends and profit payable                                           | 267.381.200           | 267.381.200              |
| Import entrustment fee                                                 | 7.971.882.400         | 43.585.842.100           |
| Advances from subscribers for shares                                   | -                     | 98.372.000.000           |
| Other short-term payables                                              | 97.943.390            | 204.160.668              |
| <b>Total</b>                                                           | <b>8.685.230.476</b>  | <b>142.747.679.592</b>   |

The Company has no other overdue payables.

**19. Borrowings and financial lease****19a. Short-term borrowings and financial lease**

|                                                                                | <u>Ending balance</u>  | <u>Beginning balance</u> |
|--------------------------------------------------------------------------------|------------------------|--------------------------|
| <b>Short-term loans from banks</b>                                             | <b>434.458.716.694</b> | <b>481.084.422.453</b>   |
| - Loan from VietinBank - An Giang Branch <sup>(i)</sup>                        | 248.217.648.347        | 246.902.476.537          |
| - Loan from PG Bank - An Giang Branch <sup>(ii)</sup>                          | 922.390.000            | 20.441.566.778           |
| - Loan from Vietcombank - An Giang Branch <sup>(iii)</sup>                     | 90.241.922.623         | 93.123.776.008           |
| - Loan from Techcombank - An Giang Branch <sup>(iv)</sup>                      | 19.499.858.733         | 82.602.553.565           |
| - Loan from Shinhan Bank Vietnam Limited – North Sai Gon Branch <sup>(v)</sup> | 29.990.232.510         | 29.996.691.421           |
| - Loan from Hong Leong Bank Vietnam Limited <sup>(vi)</sup>                    | 45.586.664.481         | 8.017.358.144            |
| <b>Short-term loans from individuals <sup>(vii)</sup></b>                      | <b>400.000.000</b>     | <b>400.000.000</b>       |
| <b>Current portions of long-term loans (see Note No. V.19b)</b>                | <b>14.400.000.000</b>  | <b>14.400.000.000</b>    |
| <b>Current portions of financial lease (see Note No. V.19b)</b>                | <b>24.018.837.022</b>  | <b>19.709.999.896</b>    |
| <b>Total</b>                                                                   | <b>473.277.553.716</b> | <b>515.594.422.349</b>   |

The Company is solvent over short-term loans and financial lease.

- (i) The loan from VietinBank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt is maximum 12 months. This loan is secured by mortgaging saving books, debt claims, inventories, buildings and structures, machinery and equipment, vehicles, office equipment and land use right of the Company (see Notes No. V.2b, V.3, V.7, V.9 and V.11).
- (ii) The loan from PG Bank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt is maximum 12 months. This loan is secured by mortgaging land use right of the Company (see Note No. V.11).
- (iii) The loan from Vietcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

is maximum 12 months. This loan is secured by mortgaging inventories, machinery and equipment and land use right of the Company (see Notes No. V.7, V.9 and V.11).

- (iv) The loan from Techcombank – An Giang Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt is maximum 12 months. This loan is secured by mortgaging right to claim debt, inventories of the Company and assets of the third party (see Notes No. V.7 and VII.1a).
- (v) Loan from Shinhan Bank Vietnam Limited - North Saigon Branch is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt is maximum 12 months. This loan is secured by assets of the third party (see Notes VII.1a).
- (vi) Loan from Hong Leong Bank Vietnam Limited is to supplement the working capital for business operation at the interest rate applied to each loan acknowledgement. The term of each loan receipt is maximum 12 months. This loan is secured by assets of the third party (see Notes VII.1a).
- (vii) The unsecured loan from external individuals and the Company's employees is to supplement the working capital for business operation at the interest rate of 7,5%/year.

Details of increases/(decreases) of short-term borrowings and financial lease during the year are as follows:

|                                         | Beginning balance      | Increase during the year | Transfer from long-term borrowings | Amount repaid during the year | Ending balance         |
|-----------------------------------------|------------------------|--------------------------|------------------------------------|-------------------------------|------------------------|
| Short-term borrowing from banks         | 481.084.422.453        | 290.133.527.081          | -                                  | (336.759.232.839)             | 434.458.716.695        |
| Short-term borrowing from individuals   | 400.000.000            | -                        | -                                  | -                             | 400.000.000            |
| Current portions of long-term borrowing | 14.400.000.000         | -                        | 7.200.000.000                      | (7.200.000.000)               | 14.400.000.000         |
| Current portions of financial lease     | 19.709.999.896         | -                        | 15.471.251.481                     | (11.162.414.356)              | 24.018.837.021         |
| <b>Total</b>                            | <b>515.594.422.349</b> | <b>290.133.527.081</b>   | <b>22.671.251.481</b>              | <b>(355.121.647.195)</b>      | <b>473.277.553.716</b> |

**19b. Long-term borrowings and financial lease**

|                                                                                                                                       | Ending balance         | Beginning balance      |
|---------------------------------------------------------------------------------------------------------------------------------------|------------------------|------------------------|
| <b>Long-term loans from banks</b>                                                                                                     | <b>82.077.000.000</b>  | <b>89.277.000.000</b>  |
| <i>Loan from VietinBank - An Giang Branch<sup>(i)</sup></i>                                                                           | <i>82.077.000.000</i>  | <i>89.277.000.000</i>  |
| <b>Financial lease</b>                                                                                                                | <b>102.258.330.663</b> | <b>27.355.435.105</b>  |
| <i>36-month financial lease from Chailease International Leasing Company Limited for business operation</i>                           | <i>12.002.280.890</i>  | <i>17.391.846.346</i>  |
| <i>36-month to 60-month financial lease from Vietnam International Leasing Company Limited for business operation</i>                 | <i>77.762.361.987</i>  | <i>9.963.588.759</i>   |
| <i>20-month to 48-month financial lease from Vietcombank Leasing Company Limited – Ho Chi Minh City Branch for business operation</i> | <i>12.493.687.786</i>  | <i>-</i>               |
| <b>Total</b>                                                                                                                          | <b>184.335.330.663</b> | <b>116.632.435.105</b> |

The Company is solvent over long-term loans and financial lease.



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

- (i) The loan from VietinBank – An Giang Branch is to pay for investment costs of the Beta-lactam antibiotic factory project at the interest rate applied to each loan acknowledgement. The loan term is 9 years starting from the first loan disbursement date. The loan is repaid on a quarterly basis and the grace period for loan principal is 16 month. This loan is secured by mortgaging buildings and structures (see Note No. V.9).

Repayment schedule of long-term borrowings and financial lease is as follows:

|                          | Total debts            | 1 year or less        | More than 1 year<br>to 5 years | More than<br>5 years  |
|--------------------------|------------------------|-----------------------|--------------------------------|-----------------------|
| <b>Ending balance</b>    |                        |                       |                                |                       |
| Long-term loans          | 96.477.000.000         | 14.400.000.000        | 57.600.000.000                 | 24.477.000.000        |
| Financial lease          | 126.277.167.685        | 24.018.837.022        | 102.258.330.663                | -                     |
| <b>Total</b>             | <b>222.754.167.685</b> | <b>38.418.837.022</b> | <b>159.858.330.663</b>         | <b>24.477.000.000</b> |
| <b>Beginning balance</b> |                        |                       |                                |                       |
| Long-term loans          | 103.677.000.000        | 14.400.000.000        | 57.600.000.000                 | 31.677.000.000        |
| Financial lease          | 47.065.435.001         | 19.709.999.896        | 27.355.435.105                 | -                     |
| <b>Total</b>             | <b>150.742.435.001</b> | <b>34.109.999.896</b> | <b>84.955.435.105</b>          | <b>31.677.000.000</b> |

Total financial lease payable is as follows:

|                                | 1 year or less        | More than 1 year<br>to 5 years | Total                  |
|--------------------------------|-----------------------|--------------------------------|------------------------|
| <b>Ending balance</b>          |                       |                                |                        |
| Principal                      | 24.018.837.022        | 102.258.330.663                | 126.277.167.685        |
| Interest                       | 3.741.776.274         | 2.641.305.073                  | 6.383.081.347          |
| <b>Financial lease payable</b> | <b>27.760.613.296</b> | <b>104.899.635.736</b>         | <b>132.660.249.032</b> |
| <b>Beginning balance</b>       |                       |                                |                        |
| Principal                      | 19.709.999.896        | 27.355.435.105                 | 47.065.435.001         |
| Interest                       | 2.853.592.223         | 1.966.340.083                  | 4.819.932.306          |
| <b>Financial lease payable</b> | <b>22.563.592.119</b> | <b>29.321.775.188</b>          | <b>51.885.367.307</b>  |

Details of increases/(decreases) of long-term borrowings and financial lease are as follows:

|                                  | Beginning<br>balance   | Increase during<br>the year | Amount repaid<br>during the year | Transfer to short-<br>term loans | Ending balance         |
|----------------------------------|------------------------|-----------------------------|----------------------------------|----------------------------------|------------------------|
| Long-term<br>loans from<br>banks | 89.277.000.000         | -                           | -                                | (7.200.000.000)                  | 82.077.000.000         |
| Financial<br>lease               | 27.355.435.105         | 108.263.626.771             | (17.889.479.732)                 | (15.471.251.481)                 | 102.258.330.663        |
| <b>Total</b>                     | <b>116.632.435.105</b> | <b>108.263.626.771</b>      | <b>(17.889.479.732)</b>          | <b>(22.671.251.481)</b>          | <b>184.335.330.663</b> |

The Company has no unpaid overdue loans and financial lease liabilities.

**20. Bonus and welfare funds**

|                                                              | Beginning balance     | Increase due to<br>appropriation for profit | Disbursement during<br>the period | Ending balance       |
|--------------------------------------------------------------|-----------------------|---------------------------------------------|-----------------------------------|----------------------|
| Bonus fund                                                   | 10.907.313.595        | 1.040.828.752                               | (11.202.548.675)                  | 745.593.672          |
| Welfare fund                                                 | 696.367.089           | -                                           | (40.000.000)                      | 656.367.089          |
| Bonus fund to Board of<br>Directors and Supervisory<br>Board | -                     | 759.195.540                                 | (759.195.540)                     | -                    |
| <b>Total</b>                                                 | <b>11.603.680.684</b> | <b>1.800.024.292</b>                        | <b>(12.001.744.215)</b>           | <b>1.401.960.761</b> |

**21. Owner's equity**



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam  
**FINANCIAL STATEMENTS**

**21a. Statement of changes in owner's equity**

Information on the changes in owner's equity is presented in the attached Appendix 02.

**21b. Details of owner's capital**

|                                | <u>Ending balance</u>  | <u>Beginning balance</u> |
|--------------------------------|------------------------|--------------------------|
| Imexpharm Corporation          | 103.486.110.000        | 80.346.370.000           |
| Lien Phat Vung Tau Corporation | 24.670.830.000         | 19.154.380.000           |
| Mr. Pham Uyen Nguyen           | 49.142.970.000         | 38.154.500.000           |
| Mr. Nguyen Van Kha             | 40.590.730.000         | 33.959.460.000           |
| Other shareholders             | 140.213.570.000        | 94.537.970.000           |
| <b>Total</b>                   | <b>358.104.210.000</b> | <b>266.152.680.000</b>   |

During the period, the Company:

(1) Issued 3.992.290 additional shares to existing shareholders through a rights offering at an exercise ratio of 20:3 (each shareholder holding 20 existing shares was entitled to subscribe for 3 new shares), in accordance with Resolution No. 02/NQ-AGP.DHD CD dated 25 August 2025, which was approved by shareholders through a written resolution.

(2) Issued 3.672.486 shares as a 2025 dividend in shares at a ratio of 25:3 (each shareholder holding 25 existing shares was entitled to receive 3 additional shares), and issued 1.530.377 shares under the Employee Stock Ownership Plan (ESOP), in accordance with Resolution No. 01/NQ-AGP.DHD CD dated 27 March 2026, as approved at the 2026 Annual General Meeting of Shareholders.

Accordingly, the Company recognized an increase of VND 91.951.530.000 in owners' contributed capital. On 21 June 2026, the Company obtained the 22nd amended Enterprise Registration Certificate issued by the Department of Finance of An Giang Province, reflecting the increase in its charter capital to VND 358.104.210.000.

**21c. Shares**

|                                          | <u>Ending balance</u> | <u>Beginning balance</u> |
|------------------------------------------|-----------------------|--------------------------|
| Number of shares registered to be issued | 35.810.421            | 26.615.268               |
| Number of shares sold to the public      | 35.810.421            | 26.615.268               |
| - Common shares                          | 35.810.421            | 26.615.268               |
| - Preferred shares                       | -                     | -                        |
| Number of shares repurchased             | -                     | -                        |
| - Common shares                          | -                     | -                        |
| - Preferred shares                       | -                     | -                        |
| Number of outstanding shares             | 35.810.421            | 26.615.268               |
| - Common shares                          | 35.810.421            | 26.615.268               |
| - Preferred shares                       | -                     | -                        |

Par value per outstanding share: VND 10.000.

**21d. Profit distribution**

The Company distributed its 2025 profit in accordance with Resolution No. 01/NQ-AGP.DHD CD dated March 27, 2026 of the 2026 Annual General Meeting of Shareholders as follows:

|                                                                                                                           | <u>VND</u>     |
|---------------------------------------------------------------------------------------------------------------------------|----------------|
| • Dividend distribution in form of shares (70,58% of profit after tax for 2025) :                                         | 36.729.060.000 |
| • Appropriation for bonus and welfare fund (2% of profit after tax for 2025) :                                            | 1.040.828.752  |
| • Appropriation for bonus fund to the Board of Directors and the Supervisory Board (1,46% of profit after tax for 2025) : | 759.195.540    |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                                                                                           |   |                       |
|-------------------------------------------------------------------------------------------|---|-----------------------|
| • Appropriation for investment and development fund (25,96% of profit after tax for 2025) | : | 13.512.353.321        |
| <b>Total</b>                                                                              |   | <b>52.041.437.613</b> |

During the period, the Company paid dividends as follows:

|              | <u>Current year</u> | <u>Previous year</u>  |
|--------------|---------------------|-----------------------|
| Dividends    | -                   | 11.343.723.000        |
| <b>Total</b> | <b>-</b>            | <b>11.343.723.000</b> |

**22. Off-Balance Sheet items****Foreign currencies**

As of the balance sheet date, cash and cash equivalents include USD 64.929,01 (Beginning balance: USD 26.528,45).

**VI. ADDITIONAL INFORMATION ON THE ITEMS PRESENTED IN THE INCOME STATEMENT****1. Revenue from sales of goods and provisions of services****1a. Gross revenue**

|                                      | <u>Current year</u>    | <u>Previous year</u>   |
|--------------------------------------|------------------------|------------------------|
| Revenue from sales of merchandise    | 3.600.061.402          | 2.046.847.470          |
| Revenue from sales of finished goods | 450.479.421.771        | 407.736.216.867        |
| <b>Total</b>                         | <b>454.079.483.173</b> | <b>409.783.064.337</b> |

**1b. Sales to related parties**

Apart from sales of goods and service provisions to its joint venture as presented in Note No. V.2c, the Company only has sales of goods and service provisions to Imexpharm Corporation (the major shareholder of the Company) for an amount of VND 10.532.044.940 (previous year: VND 12.380.518.618).

**2. Revenue deductions**

|                  | <u>Current year</u>  | <u>Previous year</u> |
|------------------|----------------------|----------------------|
| Trade discounts  | 2.453.068.792        | 1.115.668.282        |
| Sales returns    | 12.704.880           | 726.372.960          |
| Sales allowances | -                    | 15.582.789           |
| <b>Total</b>     | <b>2.465.773.672</b> | <b>1.857.624.031</b> |

**3. Net revenue from sales of goods and provisions of services**

|                                      | <u>Current year</u>    | <u>Previous year</u>   |
|--------------------------------------|------------------------|------------------------|
| Revenue from sales of merchandise    | 3.600.061.402          | 2.045.517.910          |
| Revenue from sales of finished goods | 448.013.648.099        | 405.879.922.396        |
| <b>Total</b>                         | <b>451.613.709.501</b> | <b>407.925.440.306</b> |

**4. Costs of sales**

|                              | <u>Current year</u>    | <u>Previous year</u>   |
|------------------------------|------------------------|------------------------|
| Costs of merchandise sold    | 3.325.619.648          | 1.529.706.848          |
| Costs of finished goods sold | 318.466.179.486        | 290.222.412.143        |
| <b>Total</b>                 | <b>321.791.799.134</b> | <b>291.752.118.991</b> |

**5. Financial income**

| <u>Current year</u> | <u>Previous year</u> |
|---------------------|----------------------|
|---------------------|----------------------|



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam  
**FINANCIAL STATEMENTS**

|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
|---------------------------------------------------------------------------------------------|-----------------------|-----------------------|
| Demand deposit interest                                                                     | 32.528.577            | 15.282.887            |
| Term deposit interest                                                                       | 434.139.689           | 103.561.644           |
| Dividends and profit received                                                               | -                     | 2.374.500             |
| Exchange gain arising                                                                       | 143.507.811           | 120.399.214           |
| Other financial income                                                                      | -                     | 32.735.363            |
| <b>Total</b>                                                                                | <b>610.176.077</b>    | <b>274.353.608</b>    |
| <b>6. Financial expenses</b>                                                                |                       |                       |
|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
| Loan interest expenses                                                                      | 22.393.087.563        | 18.880.133.246        |
| Exchange loss arising                                                                       | 88.040.237            | 334.192.210           |
| Cash discount given to customers                                                            | 971.484.825           | 1.311.260.939         |
| Exchange loss arising from the remeasurement of foreign currency-denominated monetary items | 116.109.385           | 330.989.924           |
| <b>Total</b>                                                                                | <b>23.568.722.010</b> | <b>20.856.576.319</b> |
| <b>7. Selling expenses</b>                                                                  |                       |                       |
|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
| Expenses for employees                                                                      | 6.502.390.906         | 7.061.096.114         |
| Tools, supplies                                                                             | 51.584.580            | 151.320.105           |
| Depreciation/(amortization) of fixed assets                                                 | 1.505.653.648         | 1.319.937.644         |
| Expenses for external services                                                              | 37.935.249.907        | 34.659.708.260        |
| <i>Commission, discount, promotion, advertisement</i>                                       | <i>33.650.351.484</i> | <i>31.471.886.851</i> |
| <i>Other external services</i>                                                              | <i>4.284.898.423</i>  | <i>3.187.821.409</i>  |
| Other expenses                                                                              | 5.205.988.046         | 3.722.071.135         |
| <b>Total</b>                                                                                | <b>51.200.867.087</b> | <b>46.914.133.258</b> |
| <b>8. General and administration expenses</b>                                               |                       |                       |
|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
| Expenses for employees                                                                      | 14.041.437.093        | 11.928.455.645        |
| Office supplies                                                                             | 1.834.019.674         | 1.855.910.446         |
| Depreciation/(amortization) of fixed assets                                                 | 321.915.104           | 474.650.822           |
| Taxes, fees and legal fees                                                                  | 141.649.258           | 57.200.126            |
| Provision for doubtful receivables                                                          | -51.500.000           | 277.861.521           |
| Expenses for external services                                                              | 3.628.711.771         | 3.612.404.457         |
| Other expenses                                                                              | 3.541.584.481         | 3.271.706.268         |
| <b>Total</b>                                                                                | <b>23.457.817.381</b> | <b>21.478.189.285</b> |
| <b>9. Other income</b>                                                                      |                       |                       |
|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
| Collection of fees for testing                                                              | 78.419.000            | 39.741.400            |
| Collection of fees for storage                                                              | 81.818.182            | 163.636.364           |
| Proceeds from liquidation, disposal of fixed assets                                         | 50.000.000            | 2.769.892.748         |
| Other income                                                                                | 10.584.000            | 185.416.121           |
| <b>Total</b>                                                                                | <b>220.821.182</b>    | <b>3.158.686.633</b>  |
| <b>10. Earnings per share</b>                                                               |                       |                       |
| <b>10a. Basic/diluted earnings per share</b>                                                |                       |                       |
|                                                                                             | <u>Current year</u>   | <u>Previous year</u>  |
| Accounting profit after corporate income tax                                                | 13.074.804.966        | 24.450.471.725        |



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                                                                                  | <u>Current year</u> | <u>Previous year</u> |
|----------------------------------------------------------------------------------|---------------------|----------------------|
| Appropriation for bonus and welfare funds (*)                                    | (261.496.099)       | (1.833.785.379)      |
| Appropriation for bonus for the Board of Directors and the Supervisory Board (*) | (190.892.153)       | (364.312.029)        |
| Profit used to calculate basic/diluted earnings per share                        | 12.622.416.714      | 22.252.374.317       |
| The weighted average number of ordinary shares outstanding during the year       | 30.224.499          | 25.702.368           |
| <b>Basic/diluted earnings per share</b>                                          | <b>418</b>          | <b>866</b>           |

(\*) The bonus and welfare fund, and bonuses for the Board of Directors and the Supervisory Board, were appropriated during the period in accordance with the appropriation ratio approved under Resolution No. 01/NQ-AGP.DHDCD dated 27 March 2026 of the 2026 Annual General Meeting of Shareholders.

The number of ordinary shares used to calculate basic/diluted earnings per share is determined as follows:

|                                                                              | <u>Current year</u> | <u>Previous year</u> |
|------------------------------------------------------------------------------|---------------------|----------------------|
| The weighted average number of ordinary shares outstanding during the period | 26.615.268          | 23.143.941           |
| Effects of ordinary shares issued during the period                          | 3.609.231           | 2.558.427            |
| <b>Average ordinary shares outstanding during the period</b>                 | <b>30.224.499</b>   | <b>25.702.368</b>    |

**10b. Other information**

There were no transactions involving ordinary shares or potential ordinary shares from the end of the reporting period to the date of issuance of the financial statements.

**11. Operating costs by factors**

|                                             | <u>Current year</u>    | <u>Previous year</u>   |
|---------------------------------------------|------------------------|------------------------|
| Materials and supplies                      | 258.464.145.447        | 265.199.830.901        |
| Labor costs                                 | 41.375.425.175         | 37.416.439.507         |
| Depreciation/(amortization) of fixed assets | 18.407.554.185         | 18.433.774.920         |
| Expenses for external services              | 49.384.728.954         | 44.351.251.841         |
| Other expenses                              | 9.874.773.296          | 8.365.197.418          |
| <b>Total</b>                                | <b>377.506.627.057</b> | <b>373.766.494.587</b> |

**VII. OTHER DISCLOSURES****1. Transactions and balances with related parties**

The Company's related parties include the key management personnel, their related individuals and other related parties.

**1a. Transactions and balances with the key management personnel and their related individuals**

The Company's key management personnel include the Board of Directors, the Supervisory Board and the Board of Management. The key management personnel's related individuals are their close family members.

*Transactions with the key management personnel and their related individuals*

The Company has no sales of goods and service provisions to the key management personnel and their related individuals and only has following transactions with the key management personnel:

| <u>Current year</u> | <u>Previous year</u> |
|---------------------|----------------------|
|---------------------|----------------------|



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS**

|                                                              | <u>Current year</u> | <u>Previous year</u> |
|--------------------------------------------------------------|---------------------|----------------------|
| Increase in contributed capital arising from share dividends | 19.198.350.000      | 7.357.380.000        |
| Share dividends distributed                                  | 10.858.790.000      | 3.678.699.000        |

*Guarantee commitment*

The Company's key management personnel used their term savings books to secure the Company's loans from Banks (see Note No. V.19a).

*Receivables from and payables to the key management personnel and their related individuals*

The Company has no receivables from and payables to the key management personnel and their related individuals.

*Remuneration of the key management personnel and the Supervisory Board*

| <u>Full name</u>        | <u>Position</u>                                       | <u>Current year</u>  | <u>Previous year</u> |
|-------------------------|-------------------------------------------------------|----------------------|----------------------|
| Ms. Pham Thi Bich Thuy  | Chairwoman cum Deputy General Director                | 250.694.900          | 218.940.950          |
| Mr. Nguyen Van Kha      | Vice Chairman cum General Director                    | 386.000.000          | 394.000.000          |
| Ms. Tran Thi Dao        | Board Member                                          | 128.000.000          | 105.000.000          |
| Mr. Nguyen Quoc Dinh    | Board Member                                          | 128.000.000          | 105.000.000          |
| Mr. Pham Uyen Nguyen    | Board Member                                          | 128.000.000          | 105.000.000          |
| Mr. Huynh Hoang Ha      | Board Member cum Deputy General Director              | 237.501.375          | 229.479.880          |
| Mr. Lam Tri Hien        | Deputy General Director                               | 75.449.315           | 64.642.240           |
| Mr. Vu Minh Tuan        | Deputy General Director                               | 72.083.845           | 82.639.411           |
| Mr. Le Van Mac          | Deputy General Director (appointed on 25 May 2026)    | 155.149.600          | -                    |
| Ms. Tran Thi Thanh Hang | Chief of the Supervisory Board                        | 126.000.000          | 104.000.000          |
| Ms. Pham Hai Yen        | Supervisory Board Member (dismissed on 27 March 2026) | -                    | 15.303.360           |
| Ms. Nguyen Thi An       | Supervisory Board Member (appointed on 27 March 2026) | 41.082.261           | -                    |
| Ms. Nguyen Hong Ngoc    | Supervisory Board Member                              | 27.000.000           | 18.000.000           |
| <b>Total</b>            |                                                       | <b>1.754.961.296</b> | <b>1.442.005.841</b> |

**1b. Transactions and balances with other related parties**

Other related parties of the Company include:

| <u>Other related parties</u> | <u>Relationship</u>                                     |
|------------------------------|---------------------------------------------------------|
| Imexpharm Corporation        | The major shareholder holding 28,90% of charter capital |
| USA-AGP Pharma, LLC          | Joint venture                                           |

*Transactions with other related parties*

Apart from transactions with the joint venture presented in Note No. V.2c and sales of goods and service provisions to other related parties presented in Note No. VI.1b, the Company only has following transactions with Imexpharm Corporation:

|                                                              | <u>Current year</u> | <u>Previous year</u> |
|--------------------------------------------------------------|---------------------|----------------------|
| Purchase of goods                                            | 4.806.213.197       | 10.412.468.510       |
| Storage fees                                                 | 81.818.182          | 163.636.364          |
| Increase in contributed capital arising from share dividends | 11.087.790.000      | 7.304.210.000        |
| Cash dividends paid                                          | -                   | 3.652.108.000        |

The prices of merchandises supplied to other related parties are market prices. The purchases of merchandises from other related parties are done at the agreed prices.



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam

**FINANCIAL STATEMENTS***Receivables from and payables to other related parties*

The receivables from and payables to other related parties are presented in Notes No. V.3 and V.13.

The receivables from other related parties are unsecured and will be paid in cash. There are no allowances for doubtful debts made for the receivables from other related parties.

**2. Segment information**

Segment information is presented based on business segments and geographical segments. Segment reporting is mainly done on the basis of business segments since the Company's business operations are organized and managed on the basis of the natures of its products.

**2a. Information on business segment**

Principal business activity of the Company is to trade finished medicines of all kinds. Additionally, other business activity of the Company is mainly sale of goods and materials. Sales from other business activity only account for a very small proportion of gross sales (0.79% of gross sales in the first six months of 2026). Sales and costs of business activities are presented in Notes No. VI.1a, VI.3 and VI.4.

**2b. Information on geographical segment**

The Company's operations include exports and local sales.

Details of net external revenue in respect of geographical segment based on the location of customers are as follows:

|              | <u>Current year</u>    | <u>Previous year</u>   |
|--------------|------------------------|------------------------|
| Domestics    | 444.754.915.310        | 403.919.490.514        |
| Overseas     | 6.858.794.191          | 4.005.949.792          |
| <b>Total</b> | <b>451.613.709.501</b> | <b>407.925.440.306</b> |

**3. Subsequent events**

There were no material events occurring after the end of the reporting period that require adjustment or disclosure in the financial statements.

Approved on July 9, 2026

**Do Thi Kim Len**  
Preparer

**Pham Do Phuong Thao**  
Acting Chief Accountant



**Nguyen Van Kha**  
Legal Representative



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam.

**FINANCIAL STATEMENTS**

For the period from January 01, 2026 to June 30, 2026

**Appendix 01: Increases/(decreases) in tangible fixed assets**

|                                                    | Unit: VND                |                         |                       |                      |                        |
|----------------------------------------------------|--------------------------|-------------------------|-----------------------|----------------------|------------------------|
|                                                    | Buildings and structures | Machinery and equipment | Vehicles              | Office equipment     | Total                  |
| <b>Historical costs</b>                            |                          |                         |                       |                      |                        |
| Beginning balance                                  | 345.741.809.657          | 137.857.621.152         | 14.744.430.215        | 4.084.788.450        | 502.428.649.474        |
| Acquisition during the year                        | 184.970.390              | 5.299.947.088           | 1.193.188.556         | 185.000.000          | 6.863.106.034          |
| Completed constructions                            | 323.087.037              | 22.862.544.233          | -                     | -                    | 23.185.631.270         |
| Increase due to transfer from finance lease assets | -                        | -                       | -                     | -                    | -                      |
| Disposals                                          | -                        | (23.548.918.239)        | (740.000.000)         | -                    | (24.288.918.239)       |
| Other decreases                                    | -                        | -                       | -                     | -                    | -                      |
| <b>Ending balance</b>                              | <b>346.249.867.084</b>   | <b>142.471.194.234</b>  | <b>15.197.618.771</b> | <b>4.269.788.450</b> | <b>508.188.468.539</b> |
| In which:                                          |                          |                         |                       |                      |                        |
| Assets fully depreciated but still in use          | 18.788.153.469           | 34.969.004.457          | 8.468.258.758         | 1.136.544.154        | 63.361.960.838         |
| Assets waiting for liquidation                     | -                        | -                       | -                     | -                    | -                      |
| <b>Depreciation</b>                                |                          |                         |                       |                      |                        |
| Beginning balance                                  | 67.755.202.311           | 99.370.934.928          | 11.665.538.628        | 1.787.578.246        | 180.579.254.113        |
| Depreciation during the year                       | 7.635.762.161            | 4.734.614.959           | 485.872.238           | 255.356.008          | 13.111.605.366         |
| Disposals                                          | -                        | (616.954.356)           | (740.000.000)         | -                    | (1.356.954.356)        |
| Other decreases                                    | -                        | -                       | -                     | -                    | -                      |
| <b>Ending balance</b>                              | <b>75.390.964.472</b>    | <b>103.488.595.531</b>  | <b>11.411.410.866</b> | <b>2.042.934.254</b> | <b>192.333.905.123</b> |
| <b>Carrying amount</b>                             |                          |                         |                       |                      |                        |
| Beginning balance                                  | 277.986.607.346          | 38.486.686.224          | 3.078.891.587         | 2.297.210.204        | 321.849.395.361        |
| <b>Ending balance</b>                              | <b>270.858.902.612</b>   | <b>38.982.598.703</b>   | <b>3.786.207.905</b>  | <b>2.226.854.196</b> | <b>315.854.563.416</b> |
| In which:                                          |                          |                         |                       |                      |                        |
| Assets temporarily not in use                      | -                        | -                       | -                     | -                    | -                      |
| Assets waiting for liquidation                     | -                        | -                       | -                     | -                    | -                      |

Approved on July 9, 2026



Do Thi Kim Len  
Preparer

Pham Do Phuong Thao  
Acting Chief Accountant

Nguyen Van Kha  
Legal Representative



**AGIMEXPHARM PHARMACEUTICAL JOINT STOCK COMPANY**

Address: No. 27 Nguyen Thai Hoc Street, Long Xuyen Ward, An Giang Province, Vietnam.

**FINANCIAL STATEMENTS**

For the period from January 01, 2026 to June 30, 2026

**Appendix 02: Statement of changes in owner's equity**

Unit: VND

|                                                                                                           | Capital                | Share premiums         | Investment and development fund | Retained earnings     | Total                  |
|-----------------------------------------------------------------------------------------------------------|------------------------|------------------------|---------------------------------|-----------------------|------------------------|
| Beginning balance of the previous period                                                                  | 231.439.410.000        | 25.726.714.700         | 93.803.543.069                  | 48.889.738.710        | 399.859.406.479        |
| Payment of dividends in form of shares in the previous period                                             | 23.141.300.000         | -                      | -                               | (23.141.300.000)      | -                      |
| Issuance of shares and collection of payment in cash in the current period                                | 11.571.970.000         | 9.257.576.000          | -                               | -                     | 20.829.546.000         |
| Profit in the previous period                                                                             | -                      | -                      | -                               | 24.450.471.725        | 24.450.471.725         |
| Appropriation for funds in the previous period                                                            | -                      | -                      | 9.777.947.742                   | (14.173.827.210)      | (4.395.879.468)        |
| Dividends and profit distributed during the period                                                        | -                      | -                      | -                               | (11.571.970.500)      | (11.571.970.500)       |
| Disbursement of funds in the previous period                                                              | -                      | -                      | (33.206.628)                    | -                     | (33.206.628)           |
| Transfer of fractional shares from dividends payment in form of shares to Bonus fund                      | -                      | -                      | 2.641.000                       | 2.641.000             | -                      |
| Ending balance of the previous period                                                                     | <u>266.152.680.000</u> | <u>34.984.290.700</u>  | <u>103.550.925.183</u>          | <u>24.450.471.725</u> | <u>429.138.367.608</u> |
| Beginning balance of the current period                                                                   | 266.152.680.000        | 34.984.290.700         | 101.242.219.168                 | 52.041.437.613        | 454.420.627.481        |
| Issuance of shares and collection of payment in cash in the current period                                | 55.226.670.000         | 71.544.766.000         | -                               | -                     | 126.771.436.000        |
| Payment of dividends in form of shares in the current period                                              | 36.724.860.000         | -                      | -                               | (36.724.860.000)      | -                      |
| Payment of dividends in form of cash in the current period                                                | -                      | -                      | -                               | -                     | -                      |
| Profit in the current period                                                                              | -                      | -                      | -                               | 26.575.564.626        | 26.575.564.626         |
| Appropriation for funds in the current period                                                             | -                      | -                      | 13.512.353.321                  | (15.312.377.613)      | (1.800.024.292)        |
| Disbursement of funds in the current period                                                               | -                      | -                      | (390.582.183)                   | -                     | (390.582.183)          |
| Transfer of fractional shares from dividends payment in form of shares to Investment and development fund | -                      | -                      | 4.200.000                       | 4.200.000             | -                      |
| Ending balance of the current period                                                                      | <u>358.104.210.000</u> | <u>106.529.056.700</u> | <u>114.368.190.306</u>          | <u>26.575.564.626</u> | <u>605.577.021.632</u> |

Approved on July 9, 2026

  
 Do Thi Kim Len  
 Preparer

  
 Pham Do Phuong Thao  
 Acting Chief Accountant

  
 Nguyen Van Kha  
 Legal Representative
